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ABSTRACT 
 The seminal discovery that the BCL2 gene inhibits cell death rather than promotes cell 
proliferation gave the foundation for a nowadays widely appreciated theory that impaired 
tumor cell death is a decisive stage in a multi-step carcinogenesis. Recognition of the central 
role of mitochondria and Bcl-2 family members in the regulation and propagation of cell 
demise has, thus, recently uncovered novel targets for selective anti-cancer therapies. In this 
context, we have for the first time demonstrated monotherapeutic potential of a small 
molecule Bcl-2 antagonist, HA14-1, against follicular lymphoma (FL) cells with t(14;18) 
translocation and Bcl-2 overexpression. In agreement with others we have shown that 
cytotoxicity mediated by a small molecule Bcl-2 inhibitor HA14-1 in FL cells proceeds 
through rapid (4h) dissipation of the ∆Ψm, generation of ROS and caspase-dependent 
apoptosis. Moreover, we were first to prove the applicability of combinatorial treatment of 
HA14-1 and selected conventional chemotherapeutics (dexamethasone and doxorubicin) in 
FL cells. In the following work we investigated the quantitative relationship between ∆Ψm 
loss and caspase activation in HA14-1 treated cells. Employing both pharmacological 
inhibitor studies and novel state-of-the-art multiparametric flow cytometry assays, we 
revealed that following HA14-1 treatment caspase activation occurs solely as a consequence 
of mitochondrial breach. Additionally, we provided new evidence that HA14-1-evoked 
apoptosis appears to be at least partially PT-dependent. We also for the first time addressed 
the cell cycle specificity of HA14-1 action using multivariate flow cytometry approaches. 
 As the interest in the role of ER and Golgi during induction/execution of apoptosis has 
been gaining momentum, they simultaneously attract growing appreciation in the 
development of novel anti-cancer therapies. Pertinent to the therapy of B-cell malignancies 
we report here for the first time the effects of an ER-Golgi transport inhibitor, Brefeldin A 
(BFA), alone and in combination with a small molecule Bcl-2 inhibitor HA14-1 or death 
receptor trigger, in the human FL cell lines bearing t(14;18) translocation. Of importance for 
future anti-cancer regimens, small molecule Bcl-2 antagonist, HA14-1 and agonistic anti-Fas 
mAb significantly enhanced BFA- mediated cytotoxicity and apoptosis, revealing novel and 
previously unexplored avenues to enhance ER-stress mediated cell killing in B-cell 
malignancies. 
 Finally, as basic studies advance towards their ultimate translational goals there is a 
need for effective and rapid analytical methods allowing high-throughput detection of diverse 
cell demise modes. In this context patented SYTO® probes are gaining increasing interest as 
easy to use markers of apoptosis. Herein, applying the state-of-the-art multiparametric flow 
cytometry and multicolor cell imaging we identified for the first time different SYTO16 
staining characteristics upon apoptotic and oncotic stimuli. We also tracked similarities and 
discrepancies between SYTO16 and ∆Ψm, sensitive probe, tertramethylrhodamine methyl 
ester (TMRM), demonstrating that stimulation with mitochondrial uncoupler FCCP and a 
small-molecule Bcl-2 inhibitor, HA14-1, induce distinct staining profiles with the decrease in 
TMRM fluorescence preceding the loss of SYTO16 fluorescence. To our knowledge this is 
the first report demonstrating such a distinct behavior of SYTO16 and TMRM and our data 
demonstrate that loss of SYTO16 is caspase-dependent, as is not a mere indicator of ∆ψm 
dissipation, postulated previously by some authors. 
 
National Library of Medicine Classification: QU 375, QY 95, QZ 350, WH 525 
Medical Subject Headings: Apoptosis; Brefeldin A; HA14-1; Cell Death; Cell Line, Tumor; 
Flow Cytometry; Genes, BCL-2; Lymphoma, Follicular; SYTO 16 
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1. Introduction 
 Every fifth person in the developed world will suffer from cancer in their lifespan. 
Therefore, the understanding of the molecular basis of cancer and mechanisms 
underlying tumor resistance to chemotherapy is of utmost importance for the 
development of novel and efficient treatment protocols.  
 Follicular lymphoma (FL), a malignancy of follicle center B cells, is the 
commonest type of indolent non-Hodgkin´s lymphoma (NHL) (Horning and 
Rosenberg, 1984; Horning, 1993). It is a heterogeneous and presently still incurable 
malignancy, characterized by a variable clinical course associated with frequent 
relapses and increasing chemoresistance to conventional anti-cancer regimens 
(Johnson et al, 1995). FL is generally characterized by the t(14;18) translocation that 
results in over-expression of anti-apoptotic Bcl-2 protein, a feature widely linked to 
the impairment of apoptosis and often correlated with enhanced resistance to 
conventional chemotherapy (Cleary et al, 1986; Vaux et al, 1988; Kirkin et al, 2004; 
Skommer et al, 2006). With the classical chemotherapy being frequently ineffective in 
achieving complete remission in FL patients, the quest for more selective, apoptosis 
targeted therapies is still ongoing (Green and Kroemer, 2005; Armstrong, 2006; 
Linder and Shoshan, 2006).  
 Classical chemotherapy regimens often trigger a mitochondrial (intrinsic) pathway 
of apoptosis, featured by the release of cytochrome c and/or other proteins residing in 
the mitochondrial intermembrane space leading to cell demise (Kim, 2005; Kim et al, 
2006). This pathway is tightly regulated by the complex regulatory network of anti-
apoptotic, and pro-apoptotic (multidomain and BH3-only) Bcl-2 family members. The 
ultimate efficacy of the conventional anticancer therapy can, thus, be heavily 
influenced by altering the fine balance between the members of the Bcl-2 family 
(Spierings et al, 2005; Skommer et al, 2007). Recognition of mitochondria and Bcl-2 
family members as the master regulators of cell demise has recently uncovered novel 
targets for anti-cancer therapies, and indeed encouraging response has been initially 
achieved in pre-clinical and early clinical trials (Gardner, 2004; Oltersdorf et al, 2005, 
Chauhan et al, 2006; Konopleva et al, 2006). Recent discovery of alternative cell 
death pathways, which involve function of until recently underappreciated organelles 
such as endoplasmic reticulum, Golgi apparatus and lysosomes, increases further the 
promises for selective anti-cancer therapy. Targeting diverse cell death pathways in 
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malignant cells slowly emerges as an alternative approach to override the commonly 
existing defects in apoptotic machinery (Ferri and Kroemer, 2001; Jäättela, 2004; 
Linder and Shoshan, 2006).  
 Finally, the rapid progress in the modern field of tumor cell death requires also 
effective and reliable methods allowing high-throughput assessment of a multitude of 
critical parameters in the studied cell population. Up to date only a flow cytometry 
(FCM) and laser scanning cytometry (LSC) deliver a single cell, high speed, 
multiparameter capability, permitting unparalleled correlation of different cellular 
events at a time (Darzynkiewicz et al, 1997; Bedner et al, 1999; Deptala et al, 2001; 
Huang et al 2005). In this regard multiparametric flow cytometry as well as laser 
scanning cytometry protocols can prove useful to study the temporal and quantitative 
relationship between a plethora of apoptotic attributes, important in basic and clinical 
cancer research studies (Darzynkiewicz et al, 1997; Halicka et al 1997; Smolewski et 
al 2003). Thus, development of novel functional probes and thorough understanding 
of the exact mechanisms underlying properties of existing ones are of utmost 
importance for the progress in cell necrobiology (Darzynkiewicz et al, 1997). In this 
context the recently described SYTO probes are slowly gaining interest as sensitive 
and easy to use markers of apoptotic cell death in basic and clinical applications 
(Frey, 1995; Poot et al 1997; van der Pol et al, 2003). However, the phenomenon 
underlying differential SYTO staining of apoptotic cells vis-à-vis normal cells is not 
fully elucidated as yet. 
 
 In the present study, applying a multitude of flow cytometry protocols, emerging 
apoptosis targeting avenues (including a small molecule Bcl-2 inhibitor; HA14-1 and 
an ER-Golgi vesicular transport disrupting drug; Brefeldin A) were explored in the 
recently established follicular lymphoma cell lines (Eray et al, 2003). Moreover, novel 
insights into mechanisms underlying discrimination between normal and apoptotic 
cells by SYTO probes were investigated using multiparameter flow cytometry and 
multicolor cell imaging platforms. 
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2. Literature overview 
2.1 Tumor cell death 
 Cancer is one of the most common causes of death in Western societies. Current 
statistics indicate rising trends in cancer incidence in the developed world (Cancer 
Research UK database http://info.cancerresearchuk.org/cancerstats). Thus, the hope to 
finally eradicate cancer is the main motivation driving the extensive cancer research 
studies over last two decades and this trend will probably continue for the decades to 
come.  
 Initial clinical perspective was that cancer is mainly characterized by the 
accelerated, uncontrolled proliferation of transformed cells leading to the 
accumulation of malignant clones in diverse organs, their subsequent dysfunction and 
fatal outcome for the patient. Thus it is of no surprise that majority of research 
activities over the past decades were targeting the cell cycle and development of 
novel, cell cycle selective drugs is still ongoing (Halicka et al, 1997; Schwartz and 
Shah, 2005). The profound contribution of tumor cell death in the process of 
tumorigenesis has only recently been brought to attention (Leist and Jaattela, 2001; 
Evan and Vousden, 2001; Crighton and Ryan, 2004). Moreover, the intense 
advancement in basic cancer research allowed our current emerging understanding 
that cancer originates not only from accumulation of genetic lesions leading to 
deregulated cell proliferation and impaired cell death but also from profound changes 
in the unique tumor microenvironment influencing both of them (Kern et al, 2004; 
Haiat et al, 2006). It is the combination of malfunctions in all those three processes 
that favors tumor development, its metastasis and finally resistance to conventional 
chemo- or radio- therapy (Haiat et al, 2006; Meinhardt at al 1999).  
 Tumor cell demise as such is an important event in the elimination of abnormal 
malignant cells and thus delivers in vivo a strong means of tumor suppression 
(Crighton and Ryan, 2004). Any genetic abnormalities incapacitating cell death 
mechanisms deliver, thus, a strong advantage for cancerous cell to succeed in evading 
both the cell intrinsic, self-check procedures and external immune surveillance (Meng 
et al., 2006). The avoidance of programmed cell death in tumorigenesis has been 
recently appreciated as one of the “hallmarks of cancer” (Hanahan and Weinberg, 
2000). Although the burden of data shows that the elimination of malignant cells 
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depends heavily on classical apoptotic pathways of cell demise, the evidence is 
mounting that other non-apoptotic mechanisms may effectively contribute to tumor 
suppression and even deliver novel anti-cancer targets (Jäättela 2004; Kroemer and 
Jäättela 2005; Levine and Yuan, 2005; Bröker et al, 2005; Kim, 2005; Kim et al, 
2006). A plethora of studies indicate that initiation of classical apoptosis is a common 
outcome of successful anti-cancer therapy (Lowe et al, 1993; Kaufmann and Gores, 
2000; Ghobrial et al., 2005). Thus a reliance of many anti-cancer drugs on apoptotic 
pathways to kill malignant cells is believed to be required for the successful cancer 
eradication and widespread dysfunctions in apoptotic machinery often render 
cancerous cells resistant to conventional chemotherapy (Zhivotovsky and Orrenius, 
2003; Ghobrial et al., 2005; Kim, 2005). In this context, multitude of successful pre-
clinical and early phase clinical studies illustrate that modulation of a diverse 
molecular signaling pathways responsible for tumor cell demise may be effectively 
utilized with a selective therapeutic intent (Ashkenazi, 2002; Meng et al, 2006; Letai, 
2005; de Thonel and Eriksson 2005; Kaufmann and Steensma 2005; Linder and 
Shoshan, 2005; Wright and Duckett, 2005; Bouchier-Hayes et al, 2005; Lavrik et al 
2005). There is a substantial hope that an increase in our understanding of the 
mechanisms responsible for tumor cell death will lead to the development of novel 
tumor-selective anti-cancer regimens (Zhivotovsky and Orrenius, 2003; Debatin, 
2004; Green and Kroemer, 2005; Fehrenbacher and Jäättela, 2005; Fischer and 
Schulze-Osthoff, 2005; Ghobrial et al., 2005).   
2.2 Many ways to cross the Hades gates 
 Extracellular and intracellular stresses reaching every normal cell in human body 
can initiate tumorigenic changes. Generally in an attempt to avoid transformation cell 
can either: 
- enter cell cycle arrest and try to repair damage and then if successful reverse 
arrest and enter again cell cycle 
- enter cell cycle arrest and if the threshold of damage exceeds the repair capacity 
survive but become senescent (discontinue its proliferative capacity – become a 
“reproductively -dead”) 
- succumb to programmed cell death if the damage exceeds the repair capacity, if 
repair processes have been unsuccessful or if initiation  of senescence program 
is impossible (Okada and Mak, 2004). 
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For many years it has been generally perceived that the cell can disassemble in two 
morphologically and biochemically distinct processes (Kerr et al, 1972; Lockshin and 
Zakeri, 2001). Classical view described apoptotic programmed cell death (PCD) and 
necrotic death being as a Dr Jekyll and Mr. Hyde for the cell commitment to death. In 
this view apoptosis was the tightly regulated execution whereas necrosis was nothing 
more then a passive and unregulated demise of the cell associated with ATP depletion 
and characterized by rapid rupture of the plasma membrane, release of cell 
constituents to the tissue environment that may lead to tissue inflammation and scar 
formation (Kerr et al, 1972; Darzynkiewicz et al 1997; Leist and Jäättela 2001). Based 
on our current knowledge, indeed, the cell that is undergoing classical apoptosis 
demonstrates multitude of characteristic and tightly regulated morphological and 
biochemical features (Kerr et al, 1972; Darzynkiewicz et al 1997; Danial and 
Korsmeyer, 2004). Some of the most characteristic attributes of apoptosis include: 
dehydration followed by cell shrinkage, loss of the mitochondrial membrane potential, 
activation of caspases and serine proteases, chromatin condensation, high molecular 
weight (HMW) followed by low molecular weight (LMW) DNA cleavage, nuclear 
fragmentation, alterations in the plasma membrane function leading to the exposure of 
the phosphatidylserine and increased plasma membrane permeability to small cationic 
probes, zeosis, disassembly of the cell into the apoptosis bodies and finally 
engulfment and elimination of the cell remnants by the professional phagocytes 
and/or the neighboring cells (Darzynkiewicz et al 1997; Petit et al 1997; Vermes et al, 
2000; Danial and Korsmeyer, 2004; Ziegler and Groscurth, 2004; Gregory and 
Brown, 2005) (Fig 1). The final outcome of apoptotic cell demise avoids ultimately 
the uncontrolled release of cellular constituents to the surrounding environment and 
protects the tissue from the development of strong inflammatory response. Activation 
of transglutaminase that leads to extensive crosslinking of protein prevents their 
release in soluble form and also has anti-inflammatory consequences. For a long time 
apoptotic cell death has, thus, been perceived as a cell death program that may 
selectively eradicate cancer with minimal adverse effects to the host.  Recently this 
view has been challenged by some authors (Brown and Vernon-Wilson, 2005). The 
evidence is slowly accumulating that excessive in situ presence of apoptotic cells may 
in fact be deleterious and deliver strong, unwanted immunomodulatory stimuli. Thus, 
the overwhelming apoptotic incidence exceeding the phagocytosis clearance capacity 
may initiate or exacerbate autoimmunological pathologies (Brown and Vernon-
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Wilson, 2005). This remarkable view on apoptotic cell death with prospectively 
serious clinical implications is to be explored during coming years (Dr Simon Brown 
– personal communication). 
 
Fig. 1 Hallmarks of apoptosis and necrosis 
 
Recent reports have also provided further insights into the mechanisms of the 
programmed death sentence and led to the characterization of several alternative cell 
death modes (caspase independent PCD, autophagy, necrosis-like PCD, mitotic 
catastrophe) with serious connotations in cancer development and treatment (Leist 
and Jäättela, 2001; Jäättela, 2002; Lockshin and Zakeri, 2002; Okada and Mak, 2004; 
Edinger and Thompson, 2004; Abraham and Shaham, 2004; Hail et al, 2006) (Tab 1).  
APOPTOSIS 
Morphological features 
Cell dehydratation & shrinkage 
Loss of pseudopodia or microvilli 
Detachment from the surface 
“Blebbing” of plasma membrane 
Chromatin condensation 
Nuclear fragmentation 
Preservation of mitochondria  
Disassembly of the Golgi apparatus 
Formation of apoptotic bodies 
Shedding of apoptotic bodies 
Engulfment and elimination by 
phagocytes/neighboring cells 
 
Biochemical features 
Preservation of ATP levels 
Loss of mitochondrial membrane potential 
Release of cytochrome c 
Activation of caspases 
Activation of endonucleases 
DNA fragmentation 
Extensive phosphorylation of histone H2AX 
General preservation of plasma membrane 
integrity (increased permeability only for very 
small cations e.g. YO-PRO1) 
Externalization of phosphatidylserine on the 
outer leaflet of plasma membrane 
Activation of transglutaminase
NECROSIS 
Morphological features 
Cell swelling 
Nuclear and mitochondrial swelling 
Vacuolization of cytoplasm 
Rupture of plasma membrane 
Dissolution of chromatin 
Dissolution of cell constituents and 
attraction of inflammatory cells 
 
 
 
 
 
 
Biochemical features 
Mitochondrial dysfunction 
Rapid depletion of intracellular 
ATP 
Lack of caspase activation 
Rapid loss of plasma membrane 
integrity 
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Based on the studies exploiting pharmacological inhibitors of caspases and genetic 
knock-out and knock-down approaches it has become evident that classical attributes 
of apoptosis may not always be manifested and the underlying mechanisms and ways 
of cell disintegration strongly depend on the cell type, cellular context (e.g. unique 
tumor microenvironment), nature of cellular insults (or initiator signals) and their 
intensity (Leist and Jäättela, 2001; Okada and Mak, 2004; Levine and Yuan, 2005; 
Lockshin and Zakeri, 2004; Edinger and Thompson, 2004; Hail et al, 2006). Recent 
observations have also delivered strong evidence of profound interorganelle cross-talk 
and involvement of diverse protease cascades leading to a finely orchestrated cellular 
disintegration. Classical apoptotic PCD as described by Kerr et al., in 1972 seems, 
thus, to no longer have exclusive rights to be called programmed.  
 
Table 1 Current concepts on the complexity of cell demise modes (based on: Leist and 
Jäättela, 2001; Okada and Mak, 2004; Jäättela, 2004; Kroemer and Jäättela, 2005) 
 
Cell demise mode Distinctive morphological features 
Distinctive 
biochemical features 
Classical apoptosis 
 
- Strong condensation of 
chromatin 
- Cell shrinkage 
- Preservation of cellular 
organelle 
- Cell membrane blebbing 
Formation of apoptotic bodies 
 
 
- Absolute requirement of 
caspase cascade activation  
- Internucleosomal DNA 
fragmentation 
- Phosphatidylserine exposure 
 
Caspase-independent 
apoptosis-like 
programmed cell death 
 
- Chromatin condensation less 
pronounced than in classical 
apoptosis 
- Varying gradation and 
combination of apoptotic 
features possible 
 
 
 
- Activation of caspases not 
necessary to execute the 
program although possible 
- Common activation of other 
proteases: cathepsins, 
calpains, serine proteases 
- DNA fragmentation less 
pronounced 
- Phosphatidylserine exposure 
often observed 
 
Autophagy 
 
- Partial chromatin condensation 
- Formation of double/multi 
layered autophagosome 
vacuoles dependent on ATG 
genes 
- Cell membrane blebbing 
possible 
 
 
- Initially perceived as caspase 
independent although recent 
reports indicate possible 
cross-talk with classical 
apoptosis 
- Lack of DNA fragmentation 
- Increased lysosomal activity 
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Mitotic catastrophe 
 
- Formation of giant polykaryons 
- Lack of chromatin condensation 
- Lack of cell membrane 
blebbing 
 
- At initial stages caspase 
independent although final 
rerouting to caspase 
dependent execution is 
possible 
- Initiated by a violation of G2 
checkpoint of the cell cycle 
and premature entry to 
mitosis 
 
Necrosis-like 
programmed cell death 
(classified also as aborted 
apoptosis) 
 
- Lack of geometric chromatin 
condensation or condensation 
forming loose speckles 
- Varying scale and combination 
of apoptotic features possible 
 
 
- Initial caspase cascade 
activation possible with 
common subsequent 
inhibition and re-routing to 
alternative pathways  
- Predominantly random 
degradation of DNA 
- Phosphatidylserine exposure 
possible 
 
Necrosis 
(classified also as 
accidental cell death or 
cell lysis) 
 
- Lack of geometric chromatin 
condensation, dissolution of 
chromatin 
- Organelle and cell swelling 
- Lack of cell membrane 
blebbing 
- Rapid rupture of plasma 
membrane 
 
 
- Lack of protease cascade 
activation 
- Random degradation of DNA 
(no DNA laddering) 
- Rapid and uncontrolled 
release of cell constituents  
Senescence 
(“cell zombie” ) 
 
- Appearance of characteristic  
heterochromatic foci 
- Characteristic flattened 
cytoplasm 
- Increased cellular granularity 
- Lack of cell membrane 
blebbing 
 
 
- Caspase independent 
- Initiated by a shortening of 
telomeres  and cell entry into 
irreversible cell cycle arrest 
(replicative senescence) 
- Profound changes in 
metabolism and activation of 
senescence-associated β-
galactosidase (SA-β-gal) 
 
 
Complicating is also fact that, depending on cellular/stimulus context, the same cell 
can often re-route its disintegrating pathways from caspase dependent cascades to 
alternative failsafe mechanisms (Bröker et al, 2005; Chipuk and Green, 2005). These 
influential discoveries initiated an ongoing debate aiming at the definition and 
classification of different modes of cell death which is of particular importance for the 
development of novel, selective anti-cancer agents (Darzynkiewicz et al, 1997; 
Zhivotovsky, 2004). The general term apoptosis, exploited commonly in many 
research articles, tend sometimes to misinterpret the actual mechanisms underlying 
cell suicide program (Leist and Jäättela, 2001; Zhivotovsky, 2004). Therefore it has 
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been recently postulated to restrict the term apoptosis to only the traditional cell 
demise program featuring all “hallmarks of apoptotic cell death”, namely: activation 
of caspases as a absolute requirement to execute cell death; tight compaction of 
chromatin to geometric figures as a result of caspase dependent DNase (CAD) action; 
appearance of distinctive cellular morphology with preservation of organelle, cell 
shrinkage, plasma membrane blebbing and nuclear fragmentation followed by 
formation of apoptotic bodies (Leist and Jäättela, 2001; Zhivotovsky, 2004; Ziegler 
and Groscurth, 2004). The use of the general term apoptosis/apoptotic events should 
be rather substituted by the name of a particular morphological and/or biochemical 
parameters measured by the investigator. Some authors proposed to use the term 
apoptosis only to define the caspase-mediated cell death (Blagosklonny, 2000). It is 
also advisable to always exploit a plethora of different assays to cross-analyze action 
of e.g. novel anti-cancer compounds and bear in mind that the characteristic changes 
in cell morphology revealed by light or electrom microscopy still remains the gold 
standard in the ultimate classification of a cellular demise mode (Darzynkiewicz, 
1997; King, 2000; Smolewski et al 2003). Proper experimental approaches will help 
to avoid any potential misclassifications as the evidences accumulate that the roads to 
cellular death represent a much more diverse and interconnected course than 
previously anticipated (Ferri and Kroemer, 2001; Leist and Jäättela, 2001; Okada and 
Mak, 2004; Chipuk and Green, 2005; Bröker et al, 2005).  
2.3 Classical apoptosis program 
 Despite our advancements in the understanding a diversity of programmed cell 
deaths, the regulation, execution and importance of the classical apoptotic program in 
tumor surveillance and chemotherapeutic drug action is so far the best understood. 
Also, at least in the case of hematological malignancies the classical apoptotic 
program seems to predominate over the alternative back-up mechanisms in cell 
response to a range of intra- and/or extracellular stressors (Rassidakis et al, 2003; 
Brown and Attardi, 2005; Skommer et al, 2007). It is conceivable, however, that 
elaborate intracellular cross-talks between classical and alternative programs exist in 
every cell type and depending on the circumstances may participate in sensing, 
initiation and amplification of the ultimate cell dismantling (Ferri and Kroemer, 2001; 
Maag et al, 2003).  
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 As described earlier one of the hallmarks of typical apoptosis is the activation of 
unique cysteine aspartyl-specific proteases having a conserved consensus site 
QACXG containing active cysteine, called caspases (from cysteinyl aspartate-specific 
proteases) (Thornberry and Lazebnik, 1998; Earnshaw et al, 1999; Zhivotovsky, 
2003; Boyce et al, 2004; Lavrik et al, 2005; Ho and Hawkins, 2005). Similar absolute 
requirement for the cleavage after aspartate residue is sheared in mammals only by 
serine protease granzyme B, making caspases a truly unique group of proteases 
(Zhivotovsky, 2003; Fadeel and Orrenius, 2005). In mammals there are probably at 
least fourteen members of the caspase family which form a closely related family of 
proteases. Nevertheless at present only eight caspases are known to participate in 
execution of apoptotic cell dismantling (caspases 2, 3, 6, 7, 8, 9, 10, 12) whereas the 
rest of the caspase family participates in cytokine processing and inflammatory 
responses (caspases 1, 4, 5, 13) (Zhivotovsky, 2003; Boyce et al, 2004; Lavrik et al, 
2005). Under normal physiological conditions caspases are constitutively expressed in 
the cytoplasm as zymogens (32 – 56 kDa) with very low intrinsic activity. They 
consist of: N-termini regulatory prodomain, a large subunit (17 – 21 kDa), linker 
region and a small subunit (10 – 13 kDa) (Earnshaw et al, 1999; Zhivotovsky, 2003). 
In response to initiator signal pro-caspases become proteolytically cleaved at specific 
aspartate residues between the large and small subunit and their pro-domains are 
being removed by the secondary proteolytical cleavage. Released small and large 
subunits dimerize and form a heterodimer which subsequently dimerizes again to 
form a fully active caspase heterotetramer (Earnshaw et al, 1999; Zhivotovsky, 2003; 
Boyce et al, 2004; Lavrik et al, 2005).  
Caspases can be divided into two subclasses with regards to their function and the 
position in the apoptotic cascade: 
- initiator caspases required for the commencement of the proteolytic cascade 
(caspase 2, caspase 8, caspase 9, caspase 10 and caspase 12)  
- executioner caspases being responsible for proteolytic cleavage of cell 
substrates leading to cell dismantling and appearance of the distinctive 
apoptotic morphology (caspase 3, caspase 6, caspase 7) (Zhivotovsky, 2003; 
Boyce et al, 2004; Lavrik et al, 2005) 
Initiator caspases feature long, regulatory prodomains with characteristic protein 
interaction motifs. Regulatory prodomains are responsible for interaction with signal 
initiator complexes where close proximity allows self-proteolysis forced activation of 
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initiator caspases (Cain et al 2002; Cain, 2003; Danial and Korsmeyer, 2004). In this 
context initiator caspases 8 and 10 are characterized by a tandem DED motif (death 
effector domains) and caspases 2, 9, 12 are characterized by a single CARD motif 
(caspase-activation recruitment domain) at the N-termini of the molecule. Executioner 
caspases lack full-size regulatory prodomains and their activation depends on the 
action of upstream initiator caspases and/or alternative mechanisms leading to their 
proteolytic activation (Ferri and Kroemer, 2001; Bröker et al, 2005; Chwieralski et al, 
2006). Once activated, caspases function in an orchestrated proteolytic cascade 
leading to its self-amplification and cleavage of specific cell substrates e.g.: ICAD, 
lamin A, actin, fodrin, gelsolin, poly-ADP-ribose polymerase (PARP) (Earnshaw et 
al, 1999; Zhivotovsky, 2003; Lavrik et al, 2005). Cleavage of cellular constituents 
does not obligatorily lead to their orchestrated disintegration but often to: 
modifications in target protein function, alterations in target protein activity level, 
uncovering alternative function of target protein and even activation of enzymatic 
function. The typical example is ICAD/CAD (Inhibitor of Caspase Activated 
DNase/Caspase Activated DNase) system where cleavage of the ICAD provides 
means to activate CAD, its translocation to nucleus and characteristic apoptotic DNA 
fragmentation.  
 Archetypically caspase activation can proceed though the two separate ways 
leading to proteolytic cascade activation: extrinsic and intrinsic pathways (Fig 2).  
 
Fig. 2 Simplistic view of extrinsic and intrinsic pathways of apoptotic cell demise 
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 Mounting evidence suggests, however, that caspase cascade can also be directly 
and efficiently launched from other intracellular organelle, like: nucleus, endoplasmic 
reticulum and Golgi apparatus with or without contribution of mitochondrial 
(intrinsic) pathway (Ferri and Kroemer, 2001; Maag et al, 2003; Hicks and 
Machamer, 2005). These fascinating aspects with direct connection to future anti-
cancer therapies will be pursued further in the following paragraphs. 
2.3.1 Extrinsic pathway 
 The most studied and thus far the best understood pathway of activating caspases 
is a receptor-linked pathway that necessitates ligation of the distinctive group of 
transmembrane receptors belonging to the Tumor Necrosis Factor α (TNF α) 
superfamily, commonly called death receptors (DR) (Fig. 2, 3) (Golstein, 1997; 
Ashkenazi and Dixit, 1999; Ashkenazi, 2002; Aggarwal, 2003; Thornburn, 2004; 
Thonel and Eriksson, 2005). Although some of DRs can transmit prosurvival 
signaling and at least under some circumstances promote cell growth, their ability to 
induce apoptosis is remarkable and probably corresponds to one of their main 
physiological functions (Ashkenazi, 2002; Aggarwal, 2003; di Pietro and Zauli, 2004; 
Park et al 2006). Up to date six distinctive DRs have been identified: TNFR1, CD95 
(FasR), TRAIL R1 (DR4) and TRAIL R2 (DR5) (TNF-Related Apoptosis Inducing 
Ligand Receptors), DR3 and DR6 (Golstein, 1997; Ashkenazi and Dixit, 1999; 
Krammer, 2000; Ashkenazi, 2002; Bhardwaj and Aggarwal, 2003; Fulda and Debatin, 
2004; Wajant et al, 2005). Important roles in regulation of immune system functions 
and tumorigenesis have been attribiuted to all death receptors. DRs are synthesized as 
monomeric transmembrane molecules whose extracellular N-termini contain three to 
four characteristic cysteine-rich domains (CRDs). The collective feature shared by all 
death receptors is a protein interaction motif located on the cytosolic tail of the 
molecule and called death domain (DDs) (Tartaglia et al, 1993; Ashkenazi, 2002). In 
addition to DRs, non-functional, so called decoy receptors (lacking or having 
truncated forms of DDs) have recently been described. They are being perceived as a 
modulatory mechanism for DRs signaling as decoys compete with DRs for the 
cognate ligands and appear not to have any supplementary biological functions 
(Sheridan et al 1997; Ashkenazi and Dixit, 1999; Ashkenazi, 2002; Kimberley and 
Screaton, 2004). 
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 Death receptors’ ligands belong to the TNF family cytokines and comprise of: 
TNF α (TNFR1 ligand), CD95L/Fas (Fas ligand), TRAIL (DR4/DR5 ligand) 
(Ashkenazi and Dixit, 1999; Ashkenazi, 2002; Aggarwal, 2003; Thorburn, 2004; 
Thonel and Eriksson, 2005). Little is still known about ligands for DR3 and DR6, and 
some reports point at TL1A and TWEAK as potential ligands for DR3. Also 
biological function of DR3 and DR6 remains up to date elusive. All ligands are 
synthesized as homotrimeric (type 2) transmembrane proteins possessing a highly 
conserved extracellular C-terminus (approximately 30% amino acid identity among 
superfamily) which can be proteolytically cleaved off to form a soluble ligand 
(Ashkenazi, 2002).  
 Activation of death receptors is executed by the ligation of the specific ligand 
(membrane bound or soluble) or agonistic monoclonal antibody which forces receptor 
trimerization, subsequent recruitment of specific adaptor proteins to their cytosolic 
death domains and formation of the DISC (Death-Inducing Signaling Complex) (Fig. 
3) (Ashkenazi, 2002; Thornburn, 2004; Thonel and Eriksson, 2005). Some reports 
postulate that death receptors can in fact exist in a pre-associated trimerized form and 
receptor ligation is rather responsible for conformational changes leading to the 
recruitment of cytosolic adaptor protein FADD (Fas Associated Death Domain) to the 
death domain (Siegel et al, 2000; Thornburn, 2004). Interestingly, there are 
indications that action of a number of anticancer drugs on the membrane lipid 
composition can lead to DRs clustering in cell membrane lipid rafts and their 
activation without involvement of specific ligands (Dimanche-Boitrel et al, 2005). 
Orthodox model assumes that during formation of the DISC, adaptor protein FADD 
(consisting of two protein interaction domains: DD – death domain and DED – death 
effector domain) binds directly or through secondary adaptor TRADD (TNFR 
Associated Death Domain - required by TNFR1) to the receptor’s death domain. 
Subsequent formation of DISC requires attraction of caspase 8/10 via homotypic 
interactions between N-terminally positioned DED motifs on the caspases and DED 
motif within FADD molecule (Fig. 3) (Chinnaiyan et al 1995; Ashkenazi, 2002; 
Thornburn, 2004; Thonel and Eriksson, 2005). Recruitment of pro-caspase 8/10 
molecules allows then their homotypic dimerization, followed by proximity forced 
processing (self-proteolysis) and formation of active caspase 8/10 heterotetramers 
(Fig. 3) (Thornburn, 2004). Active caspases 8/10 subsequently initiate proteolytic 
cascade though activation of caspase 3/6/7 and cleavage of Bid molecule which 
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interconnects death receptor with mitochondrial (intrinsic) pathway of apoptosis (Fig. 
2, 3). 
 
Fig. 3 Extrinsic pathway of apoptosis with links to caspase-independent cell demise 
pathways (based on: Leist and Jäättela, 2001; Ashkenazi, 2002; Thorburn, 2004; 
Thonel and Eriksson, 2005; Gyrd-Hansen et al, 2006) 
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step completely suffices for launching full activity of caspase 8 and processing step is 
neither essential nor sufficient for this event. It can probably only: (i) influence a 
stability of the formed dimers,; (ii) to some extend modulate its substrate specificity 
and/or, (iii) participate in the undocking of active caspase 8 from the DISC (Boatright 
et al, 2003; Donepudi et al, 2003; Thornburn, 2004; Dr Guy Salvensen – personal 
communication). Based on those data one should bear in mind that the data based on 
common assays exploiting detection of cleaved forms of caspase 8/10 on the 
Westernblots may no longer be adequate (Thornburn, 2004).  Moreover, in line with 
the above data caspase 8 has been recently reported to be shed off inside the apoptotic 
vesicles resulting in heavily underestimated activity when assessed by flow cytometry 
approaches (Packard et al, 2001). 
 Fascinatingly, specificity of caspase 8 has lately also been challenged adding 
completely new dimension to our understanding of the death receptor pathway and 
further complicating the complexity of cell demise pathways. New light has been shed 
by Jäättela and colleagues (Gyrd-Hansen et al, 2006) on the direct caspase 8-mediated 
cleavage and activation of caspase 9 (Fig. 3). Namely, caspase 8-mediated processing 
of pro-caspase 9 after TNF ligation occurs at a different site than in apoptosome-
dependent system (Asp349 instead of Asp353). Those breakthrough findings are 
bulldozing current dogma of sole caspase 9 activation after release of cytochrome c in 
the mitochondrial pathway of apoptosis (Fig 2). Remarkable evidence also exists 
linking the death receptor signaling with necrosis-like PCD, which appears to involve 
receptor interacting protein (RIP) and elaborate generation of reactive oxygen species 
(ROS) (Fig. 3) (Vercammen et al, 1998; Holler et al, 2000; Leist and Jäättela, 2001). 
 Regulation of death receptor pathway is achieved by the action of decoy receptors, 
inhibitor of apoptosis proteins (IAPs), FLICE inhibitory protein (cFLIP) and a 
plethora of signaling cascades involving PKC, PI3K and MAPK. Ubiquitinylation and 
proteasomal degradation of caspase 8 has recently been postulated to play a role in the 
regulation of extrinsic pathway (Ashkenazi, 2002; Thonel and Eriksson, 2005). 
2.3.2 Intrinsic pathway 
 The second conventional pathway of caspase activation involves the participation 
of mitochondrion and is, as a result, termed the mitochondrial (intrinsic) pathway of 
apoptosis (Fig. 2) (Danial and Korsmeyer, 2004; Green and Kroemer, 2005). Over the 
past years, the understanding of the crucial role of mitochondria and their regulators 
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in the control of apoptosis began to emerge. Early evidence connecting mitochondria 
with apoptotic cell demise conceived that pro-apoptotic and pro-survival functions of 
these organelles are quite diverse. Our progressing  knowledge indicates that, at least 
in vertebrates, this pathway of cell death is a universal response mechanism to a 
variety of physiological stresses, intended to eliminate superfluous and/or damaged 
cells (Green and Kroemer, 2005; Spierings et al, 2005; Kim et al, 2005). Intrinsic 
pathway can be reportedly initiated by e.g. the growth factor deprivation, oncogene 
activation and an excess of ROS. Moreover it has been proved that classical 
chemotherapy regimens (including DNA-damaging agents) often trigger an intrinsic 
pathway of apoptosis (Brenner et al, 2003). Undoubtedly the mitochondrion stands at 
the nexus of sensing and integrating diverse incoming stress signals, and 
mitochondrial disturbances often occur long before any marked morphological 
symptoms of apoptosis (Green, 2005; Skommer et al, 2007).  
 In recent years multiple mechanisms have been anticipated to explain 
mitochondrial function in cell death, including: release of apoptogenic proteins into 
the cytosol upon mitochondrial outer membrane permeabilization (MOMP) and loss 
of mitochondrial physiological processes indispensable for cell survival. Based on our 
current knowledge the MOMP is a fundamental event leading to a release of 
holocytochrome c (cyt c) and an array of death inducing small proteins (AIF, EndoG, 
Omi/HtrA2, Smac/DIABLO, Smac β) normally enclosed in the intermembrane space 
(IMS) of the organelle (Fig. 4) (Jiang and Wang, 2004; van Loo et al, 2002; van Gurp 
et al, 2003; Saelens et al, 2004). Although controversial, some authors postulate also 
the presence of pro-caspases (e.g. pro-caspase 3, 7, 8, 9) in the mitochondrial IMS 
which are being released during MOMP (Samali et al, 1999; Susin, et al 1999; van 
Loo et al, 2002; Garrido et al, 2006).  
 Dissipation of mitochondrial inner transmembrane potential (∆ψm) is frequently 
associated with MOMP. There are, however, examples of divergence where loss ∆ψm 
can precede, coincide or follow mitochondrial outer membrane permeabilization 
(Skommer et al, 2007). Interestingly, as described by us and others dissipation of 
mitochondrial inner transmembrane potential may not be an ultimate point of no 
return for cell commitment to die. In this regards it has been shown that in the absence 
of caspase activation some cells can reinstate mitochondrial inner transmembrane 
potential and/or eliminate damaged mitochondria (e.g. by activating autophagic 
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response) and re-establish their homeostasis (Milella et al, 2002; Wlodkowic et al, 
2006). 
 Once MOMP is initiated, the discharge of cytochrome c from the IMS occurs. 
This subsequently leads to its binding to a cytosolic protease activating factor-1 
(Apaf-1), followed by a conformational remodeling of Apaf-1, oligomerization and 
subsequent assembly of the apoptosome in the presence of dATP (Fig. 2, 4) (Hill et al, 
2003). Apoptosome forms a molecular heptametrical mega-platform (responsible for 
the recruitment and activation of apical caspase 9 (Hill et al, 2003). After apoptosome 
assembly, pro-caspase 9 is massively enlisted by homotypic interactions between 
respective CARD motifs localized in the caspase regulatory prodomain and Apaf-1. 
Conceivably, the close proximity interactions between pro-caspase 9 molecules 
attracted to the apoptosome allow their dimerization, self-proteolysis and activation 
(Hill et al, 2003). Fully active caspase 9 subunits dissociate from apoptosome 
complex and participate in the cleavage of effector pro-caspases 3/7, hence initiating 
apoptotic cell dismantling (Fig. 2).  
 Interestingly the sole release of cytochrome c and formation of apoptosome is not 
always sufficient for executing cell demise. It has been demonstrated that the presence 
of endogenous inhibitor of apoptosis proteins (IAPs) and several heat shock proteins 
(HSP; e.g. HSP 27, 60, 70, 90) can amply impede both intrinsic and extrinsic 
pathways of apoptosis, often favoring malignant cell survival (Garrido et al, 2006). 
Owing to their importance in cancer development and resistance to therapy both 
groups attract, thus, mounting attention as potential anti-cancer targets (Reed, 2003; 
Reed and Pellecchia, 2005; Meng et al, 2006). IAPs are characterized by the presence 
of zinc finger-like bacculovirus inhibitor repeat (BIR) motifs and a C-terminal RING 
domain displaying E3 ubiquitin ligase activity. They are believed to thwart process of 
pro-caspase activation downstream of MOMP, inhibit activity of mature caspases and 
participate in ubiquitin-dependent proteasomal degradation of caspases. Therefore, the 
successful activation of caspases must be facilitated by the release of additional two 
small intermembrane space proteins: Smac/DIABLO and Omi/HtrA 2 that interfere 
with IAPs’ function and allow seamless amplification of proteolytic cascade (Fig. 4) 
(van Gurp et al, 2003; Saelens et al, 2004).  
 Intriguingly, mitochondria are also reported as master regulators of caspase 
independent cell demise programs (Fig. 4) (Ferri and Kroemer, 2001; Cande et al, 
2002; Lorenzo and Susin, 2004; Kroemer and Martin, 2005). 
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Fig. 4 Downstream effects of mitochondrial outer membrane permeabilization 
(MOMP) (based on: van Loo et al, 2002; van Gurp et al, 2003; Saelens et al, 2004) 
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Smac β a recently described splice variant of Smac/DIABLO, lacking IAPs binding 
capability, exhibits considerable pro-apoptotic properties (Roberts et al, 2001). 
Although Smac β-mediated cell demise is poorly understood similar effects have been 
induced by an overexpression of truncated form of Smac/DIABLO, totally lacking its 
IAPs binding motifs (Roberts et al, 2001; van Loo et al, 2002). Thus, Omi/HtrA 2 and 
Smac/DIABLO emerge nowadays as double edge swords capable not only to 
antagonize IAPs function and promote caspase dependent apoptosis but possibly also 
to complete cell dismantling when caspase activation is pathologically abrogated. 
Topical discoveries by Vandenabeele’s group shed also light on possible role of 
FABP (fatty acid-binding protein), ACBP (Acyl-Co-A-binding protein) and PTB 
(poly-pirimidyne track-binding protein) in caspase independent regulation of cellular 
demise. Those proteins were reportedly released from isolated mitochondria upon 
treatment with recombinant tBid (van Loo et al, 2002). Even though their direct link 
to the cell death apparatus is still elusive and requires further investigation, they 
provide further evidence on the fundamental role of mitochondria on the crossroads of 
cellular life and death.  
 Owing to the importance of the above studies for our understanding of cancer 
development and advance of future anti-cancer regimens it is of no surprise that 
mitochondria and its IMS molecules represent a scientific hot-topic during recent 
years. The precise decision making at the mitochondrial level, leading to different 
death phenotypes is, however, far from fully understood. In this context, it has been 
even controversially postulated that MOMP may be a selective and rate limiting step 
in response to diversified array of death triggers. Indeed, it has been reported by some 
authors that the release of small intermembrane space proteins may be a subject to 
tight regulation and, although debatable, selectivity of MOMP in various cellular 
scenarios cannot be completely ruled out. To the best of our current knowledge the 
mitochondrial pathway of apoptosis is synchronized upstream of MOMP by a tight 
regulatory network of Bcl-2 family proteins responsible for stress sensing and 
permeabilization of the outer mitochondrial membrane (Spierings et al, 2005, 
Skommer et al, 2007). Pertinent to the importance of Bcl-2 family proteins in cancer 
biology and anti-cancer therapy, those aspects will be briefly explored in the 
following chapter.  
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2.4 Mitochondria and the Bcl-2 family – dancing with devils 
 The seminal discovery that the BCL2 gene inhibits cell death rather than promotes 
cell proliferation gave the foundation for a nowadays widely appreciated theory that 
impaired cell death is a decisive stage in a multi-step carcinogenesis (Bakhshi et al, 
1985; McDonnell et al, 1989; Spurgers et al, 2006). Actually, oncogene activation 
often promotes apoptosis, and thus cancer cells can endure only if additional survival-
promoting mechanisms are acquired (Kirkin et al, 2004; Spurgers et al, 2006). 
Following the pioneering work of Dr Stan Korsmeyer, the role of Bcl-2 family 
members in regulation of life/death switch and tumor progression has thoroughly been 
studied (Vaux et al, 1988; McDonnell et al, 1989; Nunez et al, 1990; Letai et al, 
2004). 
 Bcl-2 family members are perceived as effective watchdogs of the mitochondrial 
changes during both apoptosis and necrosis (Scorrano and Korsmeyer, 2003; Green 
and Kroemer, 2004; Chipuk et al, 2006). Novel findings postulate also their emerging 
role in the regulation of autophagy (Pattingre and Levine, 2006). Moreover, although 
traditionally linked to the regulation of mitochondrial membrane permeability, 
awareness of their unexpected functions at the endoplasmic reticulum and in cell 
cycle regulation is rising (Thomenius and Distelhorst, 2003; Gross, 2006). Importance 
of Bcl-2 proteins in sustaining viability of malignant cells is frequently exemplified 
by picturesque descriptors such as “the lords of death”, “gatekeepers and 
gatecrashers” or “bodyguards and assassins”, etc (Fleischer et al 2003; Packham and 
Stevenson, 2005). Up to date approximately 30 members of the family have been 
identified. The Bcl-2 family can be conveniently classified based on both structural 
and functional criteria on: pro-survival proteins, containing all four Bcl-2 homology 
(BH) domains (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, A1, Boo) or pro-apoptotic proteins. The 
latter cluster is further separated into multi-domain pro-apoptotic Bcl-2 proteins (Bax, 
Bak and Bok) and BH3-only proteins (Bad, Bim, Bid, Noxa, Puma, and others). 
Multi-domain pro-apoptotic proteins share a considerable degree of structural 
resemblance to pro-survival Bcl-2-like proteins and contain BH1-3 domains. BH3-
only proteins contain single BH3 domain responsible for protein-protein interactions 
(Danial and Korsmeyer, 2004; Green, 2005; Chipuk et al, 2006; Skommer et al, 
2007).  
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Fig. 5 Mutual interaction between Bcl-2 family members: A) The displacement model 
- constitutively active Bax/Bak is constrained by pro-survival Bcl-2 family members, 
counteracted by BH3-only proteins. B) The direct binding model - Bax/Bak may be 
activated only upon interaction with BH3-only activators (Bid, Bim), and Bcl-2 anti-
apoptotic proteins held this interaction in check until inhibited by de-repressor BH3-
only proteins. The transcription-independent function of p53 as a direct activator is 
also highlighted. C) Specificity of BH3-only proteins. Note that only tBid, Puma, Bim 
interact with all anti-apoptotic Bcl-2 proteins. (comprehensively reviewed in 
Skommer et al, 2007). 
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Korsmeyer, 2004; Letai, 2005; Green, 2005; Chipuk et al, 2006). Although still far 
from fully understood the complex, regulatory network of Bcl-2 proteins is being 
gradually uncovered. The conservative model (“rheostat model”) assumed that the 
anti-apoptotic Bcl-2 family members bind to the multi-domain pro-apoptotic 
members, and thus prevent them from mediating the release of cytochrome c from 
mitochondrial intermembrane space (Korsmeyer et al, 1993; Bouchier-Hayes et al, 
2005; Letai, 2005; Skommer et al, 2007). The updated, contemporary model 
(“switched-rheostat model”) implements the profound role of BH3-only molecules 
which conceivably exist in two classes: “de-repressors" and "direct activators" (Fig. 5 
A, B) (Bouchier-Hayes et al, 2005; Letai, 2005; Skommer et al, 2007). In this model, 
the BH3-only proteins can presumably bind to the hydrophobic pocket on the anti-
apoptotic Bcl-2 proteins, displacing activator BH3-only proteins (direct binding 
model), or the multi-domain pro-apoptotic family members (displacement model) 
(Fig. 5 A, B) (Bouchier-Hayes et al, 2005; Chipuk et al, 2006; Skommer et al, 2007). 
Moreover, the recent data strongly indicate that the specificity of particular BH3-only 
proteins towards anti-apoptotic members of the family seem to diverge, complicating 
further the complexity of Bcl-2 interactions (Fig. 5 C) (Letai, 2005; Skommer et al, 
2007). The final outcome of both binding models is initiation of MMP, release of 
cytochrome c, the array of previously described small intermembrane space molecules 
and initiation of apoptotic cell demise (van Gurp et al, 2003). Contemporary models 
concentrate mostly on the extensive range of molecular interactions between Bcl-2 
family proteins that occur upstream of mitochondria. The direct Bcl-2-mediated 
control of mitochondrial membrane stability is yet another scientific puzzle.  
 According to existing theories Bcl-2 family members can: 
1) insert into OMM, oligomerize, and form membrane-spanning pores 
2) interact with and regulate pre-existing channels such as permeability transition 
pore (PTP) or mitochondrial apoptosis-induced channel (MAC) 
3) temporarily alter the membrane curvature by interactions with membrane 
lipids 
4) together with heat-shock proteins regulate formation of pores from 
conglomerates of misfolded proteins in the OMM (Lemasters et al, 2002; 
Newmeyer and Ferguson-Miller, 2003; Skommer et al, 2007). 
As those mechanisms are often cell line and stimuli dependent it will probably take 
some time until we will fully comprehend the mechanistic fundamentals of MMP.  
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2.5 Inter-organelle cross-talk in sensing and executing cellular 
dismantling 
 The thorough understanding of the intrinsic and extrinsic pathways of apoptosis 
allowed gaining remarkable insights into the role and regulation of physiological and 
pathological cellular fates. The spectacular discoveries of Bcl-2 family members in 
initiation, cytochrome c/Apaf-1 in amplification and caspases in execution of cellular 
dismantling delivered, however, additional scientific riddles. The mushrooming 
studies using pharmacological inhibitors and genetic approaches provided doubts 
about the absolute universality of the mitochondrial pathway of apoptosis in response 
to many traumatic signals. Undoubtedly the fascination of a scientific community in 
the mitochondrion as a central hub controlling cell decease eclipsed for some time the 
crucial importance of other intercellular compartments. It soon became apparent, 
however, that the inhibition of caspases, overexpression of Bcl-2/IAPs, knock-out or 
knock-down of Bax/Bak/Apaf-1 does not always protect cells from dying (Rao et al, 
2002). Thus, the critical query can be raised: if the mitochondria have a dual 
physiological function what about other intracellular organelles? Does mitochondrion 
really initiates and propagates all intrinsic death signals or it only represents a simple 
cog in a more complex intracellular continuum? Since biological systems generally 
show plasticity and redundancy: what kinds of countermeasures are activated when 
mitochondrial pathway is abrogated but cell still is capable of committing suicide? 
2.5.1 Nucleus 
 Indisputably, the nuclear mechanisms regulating cell demise form the best studied 
examples of inter-organellar communications. The research in those aspects has been 
mostly driven by their enormous significance in our understanding of DNA-damage 
responses to the anti-cancer therapy (Crighton and Ryan, 2005). The seminal 
discoveries of p53 protein and further elucidation of transcription-dependent and 
transcription-independent functions of p53 delivered strong evidence of straight 
“conversation” occurring between nucleus and mitochondrion (Vogelstein et al, 
2000). Although p53 is involved in many cellular reactions like: cell cycle control, 
genome integrity maintenance, DNA repair, etc it is also considered as a watchdog of 
apoptotic cell death (Schuler and Green, 2001; Crighton and Ryan, 2005). In this 
context the DNA-damage responses, sensed by the DNA-PK, ATM and ATR protein, 
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are transduced downstream through Chk1 and Chk2 enzymes to the p53 and E2F1 
transcription factor (Fig. 6). The phosphorylation of serine residues at the N-terminal 
region of p53 leads to its stabilization and profound enhancement of trans-activation 
function (Ashcroft et al, 1999; Crighton and Ryan, 2005). A considerable number of 
apoptosis-related genes have lately been reported to be a transcriptional p53 targets 
(Schuler and Green, 2005). In this regard Bax, Puma and Bid proteins are among 
main targets that directly influence the mitochondrial pathway of apoptosis (Fig. 6) 
(Miyashita and Reed, 1995; Nakano and Vousden, 2001). The evidence exists that 
p53 can also trans-activate BH-3 only derepressor protein Noxa and a member of the 
apoptosome scaffold Apaf-1 (Oda et al, 2000; Moroni et al, 2001). Furthermore, p53 
reportedly possesses trans-repression function that down-regulates expression of anti-
apoptotic Bcl-2, Bcl-XL and IAP proteins (Schuler and Green, 2001). Also a p53-
regulated apoptosis-inducing protein 1 (p53AIP1), newly described p53 
transcriptional target, presumably locates within mitochondrial matrix and induces 
mitochondrial membrane depolarization and apoptosis when over-expressed (Fig. 6) 
(Oda et al, 2000).  
Imaginably the p53-dependent over-expression of Bax and down-regulation of Bcl-2 
can, apart of mitochondria, directly influence endoplasmic reticulum (Fig. 6). In 
support of this hypothesis, Bax overexpression has been recently found to induce Ca2+ 
mobilization from ER stores whereas convincing evidences indicate that Bcl-2 co-
localizes with ER and protects cells from thapsigargin-mediated apoptosis (Orrenius 
et al, 2003; Scorrano et al, 2003). p53 can thus supervise a deadly inter-organelle 
crosstalk, delivering further substantiation to the complex role of nucleus-ER-
mitochondria network in initiation and propagation of programmed cell suicide.  
 Fascinatingly, recent discoveries shed surprising light on the transcription-
independent role of p53 in apoptosis (Chipuk et al, 2003; Chipuk and Green, 2003). In 
this context, p53 has been reported to directly translocate to mitochondria and to 
interact with pro- and anti-apoptotic Bcl-2 family members acting as an enabler and 
de-repressor protein, respectively. (Chipuk and Green 2003; Chipuk and Green, 2004; 
Skommer et al, 2006). Thus, the p53 protein seems to present analogical properties as 
earlier described BH3-only proteins. Conceivably the transcription-independent action 
of p53, generate an initial wave of cellular response to stress, backed subsequently by 
a secondary, transcription-dependent mobilization of e.g. Bax, Puma and Noxa. This 
model of p53 vs. Bcl-2 crosstalk has been extensively reviewed by us and others 
 35
(Chipuk and Green 2003; Chipuk and Green, 2004; Skommer et al, 2007). In 
conclusion p53 lures as an evolutionary conserved, multifunctional cog sitting on the 
crossroad of life and death. It is feasible, however, that because of its fundamental 
function further, yet unexpected p53’s associations are to become apparent in the 
forthcoming years. 
 It is noteworthy to highlight at this point that although widely appreciated, p53 is 
not a sole tumor suppressor acting in response to oncogenic stimulation and DNA 
damage. Recent discovery of the close p53 homologues (p63 and p73) allowed the 
recognition of p53-p63-p73 regulatory axis that complicated event more the 
overwhelming complexity of the tumor suppressor’s network (Muller et al 2006; Pluta 
et al 2006). Lately revealed homologues use numerous promoters to produce a display 
of splicing forms. They are implicated both in normal tissue development and in 
tumor formation (DeYoung and Ellisen, 2007). P63 and p73 reportedly play an 
important role in apoptosis initiation by, similarly to p53, transactivating pro-
apoptotic (e.g. CD95, TNFR1, TRAILR1, Bax, PUMA, Apaf-1) and transrepressing 
anti-apoptotic genes (e.g. HSP-70) (Muller et al 2006). Although still controversial, 
the mushrooming evidence indicates important roles of both homologues in 
progression of human malignancies and their responses to the anti-cancer therapy 
(Muller et al 2006; Pluta et al 2006). Interestingly, p63 and p73 isoforms come in 
many flavors including full length and N-termini truncated forms, which can act as 
transactivators of downstream targets or dominant negative repressors, respectively.  
 The ∆N-isoforms of p63 and p73 are postulated to have substantial oncogenic 
potential and contribute to cancer chemoresistance (Muller et al 2006). Current in 
vivo data suggest that p53 homologues may not function as conventional tumor 
suppressors as they are rarely mutated in human cancers and p73 deletion does not 
accelerate tumorigenesis in murine models (Perez-Losada et al 2005, Muller et al 
2006). Likely it is the composition of different isoforms present in specific tissue 
context and unique tumor microenvironment signals that shape the dependence of 
different strains of the p53-p63-p73 regulatory axis (Muller et al 2006).  
 Aiming at the therapeutic implications of the p73 gene, the group led by Dr Kevin 
Ryan (Beatson Institute for Cancer Research, Glasgow, UK) has only recently 
reported a novel p53-derived apoptotic peptide (37AA hybrid peptide) that by de-
repressing p73 from its negative regulator iASPP induces p73-dependent cell death in 
vitro and tumor regression in vivo (Bell et al 2007). Of note, 37AA-evoked cell death 
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was independent of the p53 status and selective to malignant cells (Bell et al 2007). It 
is of particular importance as nearly 50% human tumors feature loss or mutations of 
p53, yet frequency of human p73 mutations appears to be extremely low. Thus, there 
is a substantial hope that by reinstating the pro-apoptotic function of p73 we will be 
able to robustly eradicate p53 mutant/p73 WT tumors (DeYoung and Ellisen 2007; 
Bell et al 2007). 
2.5.2 Secretory pathway 
 For decades our knowledge on the pro-survival physiological functions of 
endoplasmic reticulum, Golgi apparatus, endosomal/lysosomal compartment, 
cytoskeleton and plasma membrane intensively evolved. We gained profound insights 
into the dynamic interaction between e.g. endoplasmic reticulum-Golgi apparatus-
lysosomal-endosomal compartments and their direct structural/functional complexity 
in the rigid inter-organelle crosstalk required for cell endurance. Yet the assumption 
that every cell organelle is conceivably capable of sensing, amplificating and 
executing cell death is still a relatively novel and unexplored conundrum (Ferri and 
Kroemer, 2001; Maag et al, 2003; Momoi, 2004; Hicks and Machamer, 2005; 
Szegezdi et al, 2006). As recently shown by many authors, the secretory pathway is 
actively involved in sensing, launching and executing cellular demise (Fig. 6) (Maag 
et al, 2003). Moreover the evidence exists that decision making at the level of 
endoplasmic reticulum and Golgi apparatus may activate both pro-survival (recovery) 
mechanisms and, if the traumatic threshold is exceeded, cell suicide programs (Maag 
et al, 2003; Hicks and Machamer, 2005). The intense protein trafficking between ER-
Golgi-endosomal/lysosomal compartments conceivably allows precise damage 
sensing and subsequent signal integration (Ferri and Kroemer, 2001; Maag et al, 
2003). Together with the elements of secretory pathway, the mitochondrion and 
members of the Bcl-2 family often participate in integrating incoming death 
messages. The evidence is also mounting that signals initiated at the ER-Golgi 
network may possibly bypass mitochondrion and directly participate in carrying out 
the finely orchestrated cellular dismantling (Fig. 6) (Maag et al, 2003; Machamer, 
2003).   
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 Endoplasmic reticulum (ER) 
 The involvement of endoplasmic reticulum in stress sensing encompasses two 
mainstream mechanisms: unfolded protein response (UPR) and calcium signaling (Fig 
6, 7). UPR can be further divided into a transcription-dependent and transcription-
independent mechanisms; the former heavily involved in initial cell recovery 
pathways (Ferri and Kroemer, 2001; Rutkowski and Kaufman, 2004; Walter and 
Hajnoczky, 2005). 
 Transcription-dependent response in initiating cell dismantling 
 The accumulation of unfolded proteins in response to traumatic stimuli (e.g. 
inhibition of N-linked glycosylation by tunicamycin; disruption of ER-Golgi vesicular 
transport by brefeldin A or deficient formation of disulfide bonds by dithiothreitol) 
leads to their competitive binding to ER-luminal chaperon BiP/GRP78 (Bertolotti et 
al, 2000; Rutkowski and Kaufman, 2004). It displaces BiP/GRP78 form the ER-
membrane residual serine-threonine kinase Ire1-α, allowing its dimerization and 
autophosphorylation on a cytosolic tail (Fig. 7). Following activation, the cytosolic 
fragment of Ire1-α undergoes cleavage by preselin-1 (PS-1) and translocates to 
nucleus where it promotes transcription of endoplasmic-resident chaperones (BiP, 
calreticulin) and transcription factor CHOP/GADD 153 (Fig. 7) (Katayama et al, 
1999; Patil and Walter, 2001; Ferri and Kroemer, 2001). In the context of cellular 
demise CHOP/GADD 153 has been shown to down-regulate Bcl-2 expression and 
thus initiate mitochondrial apoptotic program (Fig. 7) (McCullough et al, 2001). 
Moreover, tunicamycin-induced ER-stress has recently been found to up-regulate 
expression of TRAIL receptor DR5 through CHOP/GADD 153 transcription factor in 
human prostate and carcinoma cells (Shiraishi et al, 2005). Intriguingly, the p53-
mediated trans-activation of Puma and Noxa in response to thapsigargin and 
tunicamycin has been demonstrated in the recent work of Li and colleagues (Fig. 7) 
(Li et al, 2006). Although ER UPR-p53 link still remains elusive it delivers novel 
insights on the complexity of cellular signaling launched in response to secretory 
pathway stressors. 
 
 Transcription-independent response in initiating cell dismantling 
 Following activation, Ire1-α reportedly attracts adaptor protein TRAF-2 (TNFR-
associated protein 2) (Yoneda et al, 2001). Formation of Ire1-α/TRAF-2 complexes at 
the cytosolic face of ER is postulated to activate c-Jun N-terminal kinase (JNK) 
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pathway and/or participate in recruitment, clustering and auto-activation of pro-
caspase 12 molecules (Fig. 7) (Urano et al, 2000; Yoneda et al, 2001).  
 
Fig. 7 Initiation of cell demise pathways in response to the ER stress (simplified and 
based on: Ferri and Kroemer, 2001; Momoi, 2004; Walter and Hajnoczy, 2005) 
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only protein Bim, hence strongly influence mitochondrial-targeted pro-apoptotic 
signaling (Lei and Davis, 2003; Momoi, 2004; Szegezdi et al, 2006).  
 The discovery of the caspase 12 as an apical enzyme involved in response to ER 
damage delivered novel, speculative links to the classical apoptotic machinery (van de 
Craen et al, 1997). Although functionally present only in rodents, caspase 12, is 
localized specifically to the cytosolic side of endoplasmic reticulum (Nakagawa et al, 
2000). Its activation in mouse embryonic fibroblasts has been reported to exclusively 
follow ER-targeted stress stimuli like: brefeldin A, tunicamycin and thapsigargin 
(Momoi, 2004). Moreover, inhibition of caspase 12 activity by overexpression of its 
endogenous inhibitor MAGE-3 has been reported to diminish ER-stress mediated 
apoptotic response in mouse cells (Fig. 6) (Morishima et al, 2002; Maag et al, 2003). 
There are, however, still conflicting reports on the requirement of caspase 12 in the 
ER stress response (Nakagawa et al, 2000; Momoi, 2004). Apart from Ire1-α/TRAF-
2-mediated auto-proteolysis, several alternative models of activation have lately been 
proposed for caspase 12, including: Ca2+-dependent cleavage by m-calpain; CARD 
domain-mediated clustering on an undefined Apaf-1-like adaptor molecule; GRP78 
mediated formation of caspase 7/caspase 12 dimers (Momoi, 2004). As humans lack 
functional caspase 12 the quest is still ongoing to decipher its exact human orthologue 
(Fischer et al, 2002; Momoi, 2004). In this context caspase 4 has been recently 
demonstrated to co-localize with and participate in ER-induced apoptosis (Hitomi et 
al 2004). Complicating the complexity of apoptotic pathways an isoform of pro-
caspase 8, pro-caspase 8L, has also been found to be activated at the ER via 
interaction with Bap31 protein (Breckenridge et al, 2002). 
 Finally, stress signals culminating at the endoplasmic reticulum can trigger rapid 
Ca2+ release from luminal ER stores. This process is efficiently executed by the 
inositol-1,4,5-triphosphate receptors (IP3Rs) or ryanodine receptors (RyRs) serving as 
Ca2+ channels (Fig. 7) (Orrenius et al, 2003; Walter and Hajnoczy, 2005). Both pro- 
and anti-apoptotic members of the Bcl-2 family have also been postulated in 
regulation of the ER Ca2+ homeostasis (Thomenius and Distelhorst, 2003; Chen et al, 
2004; Walter and Hajnoczy, 2005). Moreover as mitochondria often show close 
proximity contacts with tubular ER network their interactions cannot be without an 
influence on the inter-organelle information transfer (Rizzuto et al, 1998; Mannella et 
al, 1998). In this regard, recent work of Boehning and colleagues illustrated novel 
insight into the ER-mitochondrion crosstalk at the very early stages of apoptosis 
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induction. Clearly the initial cytochrome c release may initiate the activation of IP3Rs, 
Ca2+ discharge from ER and subsequent feedback on mitochondria in the shape of by 
PTP dependent MMP (Fig. 7) (Boehning et al, 2003; Walter and Hajnoczy, 2005).  
Apart from eliciting mitochondrial MMP, the rapid Ca2+ mobilization from ER lumen 
can also elicit activation of cytosolic Ca2+-dependent proteases, calpains. They are 
being seemingly involved in both caspase 12 processing and sole propagation of 
cellular dismantling (Fig. 6, 7) (Nakagawa and Yuan, 2000; Guicciardi and Gores, 
2003). 
 Golgi apparatus 
 It has been known for some time that Golgi apparatus is being dissembled during 
apoptosis in a manner similar to that observed during mitosis (Sesso et al, 1999). 
Apoptotic cleavage of structural proteins localized to the Golgi has recently been 
found necessary to dismantle complex Golgi structure into separate stacks of cisternal 
membranes. In this context the overexpression of non-cleavable forms of structural 
golgin-160, p115 and GRASP65 often delay Golgi separation during caspase 
dependent cell death (Mancini et al, 2000; Chiu et al, 2002; Lane et al, 2002; Maag et 
al 2003). Yet a concept that Golgi apparatus may actually be actively involved in 
initiation and/or execution of cellular demise delivers a completely new insight on the 
secretory pathway as a watchdog of cellular fate (Maag et al, 2003; Machamer 2003; 
Hicks and Machamer, 2005).  
 The seminal discovery of caspase 2 and its co-localization to the Golgi apparatus 
and the nucleus delivered initial suggestions that Golgi apparatus may not only be “a 
passive player” in apoptosis (Fig. 6) (Mancini et al, 2000). Although caspase 2 has 
also been found to participate in DNA damage responses it conjunction with 
PIDDosome complex, it is reasonable that its function may be bidirectional and 
depend heavily on the cellular compartmentalization (Tinel and Tschopp, 2004; 
Zhivotovsky and Orrenius, 2005; Hicks and Machamer 2005). Pertinent to this notion 
it is now generally believed that a pool of caspase 2 localized at the cytosolic side of 
the Golgi apparatus may participate in initiation of apoptotic cascade in response to 
secretory pathway stresses. In support of this concept specific caspase 2-dependent 
cleavage of golgin 160 at Asp59 site has been shown as a very early apoptotic event 
that preceded caspase 3-dependent cleavage of golgin160 and poly-ADP-ribose 
polymerase (PARP) (Mancini et al, 2000; Machamer 2003). Captivatingly, recent 
report by Machamer’s group provided further evidence that caspase-resistant mutant 
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golgin 160 can abrogate apoptosis induced specifically by ER stress and ligation of 
death receptors (Maag et al, 2005). Moreover, BRUCE (baculoviral-IAP-repeat-
containing ubiquitin-conjugating enzyme) an expected negative regulator of caspase 2 
activity has been localized to the Golgi superstructure (Fig. 6) (Hauser et al, 1998; 
Maag et al, 2003). 
 Besides caspase 2, the role of glycolipids and ceramides as messengers in death 
signalling pathways has also been raised during recent years. In the Golgi context, the 
activity of the GD3 synthase reportedly converts ceramide to the gangliosyde GD3. 
The latter has been shown to translocate to the mitochondrion and solely trigger MMP 
(Fig. 6) (Rippo et al, 2000; Malisan and Testi, 2002). Interestingly the suppression of 
GD3 synthase activity or its retention in the ER lumen markedly inhibits apoptosis 
(Tomassini et al, 2004). Moreover there are hints that mitochondrial GD3 targets are 
under rigid control of anti-apoptotic Bcl-2 family members (Malisan and Testi, 2002). 
Similarly to the GD3, a semilysobisphosphatidic acid has been found to shuttle from 
the Golgi to mitochondria in response to death receptor stimulation, supporting the 
significance of inter-organelle lipid signalling pathways (Cristea and Degli Esposti, 
2004). 
 It is also conceivable that a pool of death receptors that populate Golgi apparatus 
in the normal physiological conditions demonstrate yet another link between Golgi 
and initiation of cellular demise (Ferri and Kroemer, 200; Maag et al, 2003). Some 
reports indicate that DRs may be quickly mobilised and shuttled to the cell surface 
during in response to p53 or GD3 signalling (Bennett t al, 1998; Maag et al, 2003). 
Moreover it is tempting to speculate that during apoptotic Golgi disassembly a surge 
release of DRs occurs which amplifies further the death cascade. 
 
 Not surprisingly Golgi apparatus lures as the upstream controller of many 
destruction cascades. The active protein transfer between ER-Golgi requires precise 
control mechanisms that as such are supposedly very sensitive to every pathological 
alteration in cellular homeostasis (Hicks and Machamer, 2005). Moreover the stability 
of steady-sate Golgi configuration is achieved not only by a subtle balance between 
antegrade vis-à-vis retrograde membrane trafficking but also by the specialized 
structural proteins like golgins and GRAPs involved in vesicle tethering and docking 
interactions between separate Golgi stacks (Hicks and Machamer, 2000). Cleavage 
fragments of golgins have been demonstrated to contain nuclear targeting motifs, 
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implicating further their role in the inter-organelle signal transduction (Mancini et al, 
2000; Hicks and Machamer, 2002; Chiu et al, 2002). Furthermore, as postulated 
recently, Golgi is in fact enclosed in a highly specialized exoskeleton vigorously 
implicated in membrane anchoring, regulation of substrate diffusion and even enzyme 
positioning (Hicks and Machamer, 2005). It is plausible to speculate that unique Golgi 
exoskeleton may take part in integrating a plethora of death stimuli engaging from 
other parts of the cytoskeleton. Although speculative, the unique structure exoskeleton 
may have evolved to sense any distressing changes in the Golgi cisternal structure. In 
this regard any pathological physical abnormalities like: cisternal swelling, 
unstacking, alterations in membrane curvature or even thickness in Golgi membranes 
could hypothetically initiate recruitment of specific adaptor molecules that transduce 
cell recovery or cell demise signals (Hicks and Machamer, 2005).  
 Finally, Golgi apparatus is conceivably equipped with effective UPR sensing 
mechanisms compulsory to remove any misfolded or mutated proteins that escaped 
aforementioned ER-UPR system (Arvan et al, 2002; Hicks and Machamer, 2005). 
Therefore any overload of misfolded proteins reaching Golgi may set off initial cell 
recovery mechanisms and when they prove to be ineffective also cell demise 
pathways. Keeping in mind the crucial physiological position of this organelle it is 
tempting to speculate that, similarly to mitochondrion and endoplasmic reticulum, 
Golgi is poised to sense and integrate diversified death signals (Hicks and Machamer, 
2005). Although the precise signalling pathways are still elusive it is unlikely that we 
will need to wait long for these questions to be answered. 
2.6 Selective targeting of cell demise pathways in cancer 
therapy 
 Thanks to seminal discoveries in recent years it now becomes apparent that 
extensive inter-organelle crosstalk that regulates orchestrated cell dismantling is 
present in every cell type. Even if mitochondrion reportedly stands at the nexus of 
controlling cell fate in many models, redundant and failsafe mechanisms commencing 
from other organelles do exist and may in many cases efficiently override the 
inhibition of classical pathways. In this context, the importance of the organelle 
specific initiation of cell death signals is profoundly highlighted in cancer research 
field where the quest to override the intrinsic resistance of malignant clones to 
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apoptosis has direct links to the treatment outcome (Ferri and Kroemer, 2001; Kitada 
et al, 2002; Packham and Stevenson, 2005; Skommer et al, 2006).  
 Undoubtedly the appreciation of the death receptor pathway and recognition of the 
central role of mitochondria/Bcl-2 family members in the regulation and propagation 
of cell demise has uncovered novel targets for anti-cancer therapies (Pellecchia and 
Reed, 2004; Reed and Pellecchia, 2005; Fantin and Leder, 2006).The alternative cell 
death pathways involving until recently underappreciated organelles such as 
endoplasmic reticulum, Golgi apparatus and lysosomes are, however, beginning to 
mushroom (Ferri and Kroemer, 2001; Jäättelä, 2004; Hicks and Machamer, 2005).  
 Thus, the present hope prevails that exploration of novel, non-redundant, fail-safe 
pathways of cell destruction might prospectively provide effective means to override 
cancer chemo-resistance (Anether et al, 2003; Linder and Shoshan, 2005; Kroemer 
and Jäättelä, 2005; Kim et al, 2006; Carew et al, 2006). The selected apoptosis based 
anti-cancer strategies with importance to the present thesis will be shortly discussed 
below.  
2.6.1 A one shot kill - death ligands in cancer therapy 
 The opportunity of directly activating apoptotic program in malignant cells 
attracted considerable interest since the discovery of death receptor pathway.  
Originally, the FasL and TNFα ligands have been shown to possess remarkable in 
vitro anticancer properties against a wide panel of tumor cell lines and primary, 
patient derived samples. Although initial prospects seemed optimistic subsequent 
reports, utilizing in vivo models, proved that both ligands lack specificity and are 
excessively toxic to normal tissues (Meng et al, 2006; Ricci and Zong, 2006). 
Substantial side effects including hemorrhagic lesions, septic shock and hepatic 
failure in animal models excluded, thus, their further systemic administration (Ricci 
and Zong, 2006). Interestingly, TNFα found its restricted, investigational application 
for treatment of melanoma in isolated limb perfusion system (Ricci and Zong, 2006).  
 Although disappointing from the clinical perspective, the results achieved on Fas 
and TNF systems boosted further research on the therapeutic exploitation of death 
receptor pathway. The year 1996 marks the independent discovery of APO2L/TRAIL 
(APO2 ligand/TNF-related apoptosis-inducting ligand) by groups at the University of 
Michigan and biotech company Human Genome Sciences (HGS) in Rockville 
(Garber, 2005; Ricci and Zong, 2006). Extensive studies on TRAIL and its 5 receptors 
 45
(refer to the chapter 2.3.1 and Ashenazi, 2002) have delivered novel premises for DRs 
targeted therapies as cytotoxicity of TRAIL has reportedly been limited to tumor 
cells. Because TRAIL targeted therapies have potential to spare normal cells while 
inducing massive apoptosis in malignant cells they have recently been approved by 
FDA for clinical trials in patients with: advanced solid tumors, colon cancer, NSLC 
and NHLs (Meng et al, 2006).  
 Current development of effective medicines is funneled into two separate 
concepts: 1) utilization of stable, recombinant TRAIL ligand (led by Genentech – 
Amgen collaborative partnership; currently in phase 1 clinical trails) and 2) 
development of agonistic (activating) monoclonal antibodies against both DR4 and 
DR5 receptors (led by Human Genome Sciences; antibodies HGS-ETR1, HGS-ETR2 
currently in phase 1/2 clinical trails) (Garber, 2005; Duiker et al, 2006; Ricci and 
Zong, 2006). Both concepts are being developed as single agent regimens and as a 
combinatorial approach with contemporary cytotoxic drugs (Ghobrial et al, 2005; 
Duiker et al, 2006). 
 The main impediment of the DRs based therapies is associated with reported 
resistance to TRAIL in majority of solid tumor cell lines (Meng et al, 2006; Duiker et 
al, 2006). Therefore, there is currently a substantial interest in modulation of DRs 
action and development of combinatorial treatment scenarios weakening or overriding 
tumor TRAIL-resistance (Meng et al, 2006). Moreover as the physiological functions 
of TRAIL still remain elusive there are unknown risk factors which have to be 
included into the ultimate therapeutic equation (Diehl et al, 2004; Garber, 2005). 
2.6.2 Targeting Bcl-2 family members 
 As oncogene activation often promotes cell demise, cancer cells can survive only 
if they counterbalance intrinsic death signals by e.g. inactivation of p53-dependent 
pathway or over-expression of anti-apoptotic Bcl-2 family members (Spurgers et al, 
2006). In this context, over-expression of Bcl-2, Bcl-XL and/or Mcl-1, or loss of Bak 
and/or Bax function, has been suggested to contribute to tumor resistance to a wide 
array of conventional treatment protocols (Cory and Adams, 2005; Spurgers et al, 
2006). Overexpression of BCL-2 gene is found in most follicular lymphoma, chronic 
lymphocytic leukemia and a quarter of large B-cell non-Hodgkin lymphomas. Also 
solid tumors including: prostate cancer, breast cancer, small cell lung carcinomas and 
non-small cell lung carcinomas, melanoma and gliomas feature pathological 
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overexpression of BCL-2 related genes (Letai et al, 2004). Although defects in the 
ability to initiate cell demise program have been linked to cancer development and 
correlated with chemotherapy failure, cancerous cells feature a unique “Achilles´ 
heel”. As the core components of their death machinery always remains intact they 
are intrinsically “primed to death” by intrinsic genomic instability, violation of cell 
cycle checkpoints, anoikis, etc, which are all postulated to activate pro-apoptotic Bcl-
2 family members (Fig. 8) (Cory and Adams, 2005; Certo et al, 2006; Del Gaizo 
Moore et al, 2007). According to this theory, malignant cells are being “addicted” to 
prosurvival lesions and therapeutic agents able to restore cell demise machinery are 
expected to selectively eliminate malignant cells while sparing their normal 
counterparts not “primed to decease” (Letai et al, 2004; Certo et al, 2006; Del Gaizo 
Moore et al, 2007). It is of no surprise then that the recognition of the central role of 
mitochondria and Bcl-2 family in the regulation of cell demise has in recent decade 
uncovered novel targets for anti-cancer therapies (Cory and Adams, 2005; Letai, 
2005). The cornerstone for current anti-Bcl-2 therapies has been laid by the influential 
research of Dr Stan Korsmeyer and his “Bcl-2 rheostat” hypothesis postulated back in 
1994 (refer to chapter 2.4 and Skommer et al, 2006). Especially the anti-apoptotic 
members of Bcl-2 family (Bcl-2, Bcl-XL, Mcl-1, Bcl-W, Bfl-1 and Bcl-B) represent 
the core interest in the rational drug design (Adams et al, 2005; Letai, 2005; Reed and 
Pellecchia, 2005). Current attempts to overcome cytoprotective effects exerted by 
anti-apoptotic Bcl-2 proteins in cancer cells, include development of drugs: 1) 
silencing the Bcl-2 gene expression; 2) enhancing expression of endogenous 
antagonists of Bcl-2; 3) inducing mRNA degradation with antisense oligonucleotides 
and 4) directly targeting protein-protein interaction using small-molecule inhibitors 
(Reed and Pellecchia, 2005). 
 As a proof of principle, the most advanced drug, Bcl-2 antisense oligonucleotide 
(oblimersen sodium, G3139, Genesense) has been successfully approved for clinical 
trials in non-Hodgkin's lymphomas and chronic lymphocytic leukemia (Meng et al, 
2006). The drug has been designed against first six codons of the Bcl-2 and reported 
to synergize with conventional chemotherapeutics (e.g. DNA cross-linking agents and 
glucocorticoids). The major disadvantages of the antisense strategy are, however, the 
slow degradation rate of the Bcl-2 protein (which necessitates a prolonged 
suppression of mRNA accumulation) and potential inflammatory responses. 
Unfortunately recent results from phase III clinical trials were disappointing.  In 
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multiple myeloma study oblimersen sodium failed to improve progression free 
survival in combination with dexamethasone. Likewise unsatisfactory results were 
obtained in chronic lymphocytic leukemia and melanoma studies (Ghobrial et al, 
2006). G3139 was also disqualified from therapeutic dose escalation due to 
substantial off-target effects resulting in e.g. thrompocytopenia (Ghobrial et al, 2006). 
Finally recent reports by Raffo et al (2004) and Benimetskaya et al (2004) provided 
evidence that G3139 exerts its cytotoxic potential even in Bcl-2 depleted cells, raising 
uncertainty regarding specificity of the drug. 
 Conversely to antisense strategy, small molecule, cell permeable inhibitors of anti-
apoptotic Bcl-2 family members are believed to have a wider therapeutic window 
with reduced potential to initiate unfavorable immune response (Fig. 8).  
 
Fig. 8 Mechanisms underlying expected efficacy of the small molecule Bcl-2 
antagonists 
 
 
 The mechanism of Bcl-2 antagonist action is based on the disruption of protein-
protein interactions between pro- and anti-apoptotic Bcl-2 family members (Cory and 
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mimetics”. “BH3 mimetics” have the potential to bind to the hydrophobic cleft on the 
surface of anti-apoptotic Bcl-2 proteins and by displacing pro-apoptotic multidomain 
and BH3-only proteins initiate intrinsic program of cell demise (Letai et al, 2002). 
The proof of concept for Bcl-2 antagonists was initially provided by studies on 
recombinant BH3 domains derived from Bid, Bim and Bad (Letai et al, 2002; 
Walensky et al, 2004; Certo et al, 2006). Considerable attention is currently being 
attracted to natural as well as synthetic peptide and non-peptide inhibitors of the Bcl-2 
family members, differing in their specificity, efficacy and attainability in vivo (Letai, 
2005; Reed and Pellecchia, 2005).  
 Pertinent to the therapeutic potential, small molecule "BH3 mimetics" effectively 
induce apoptosis in diverse cell lines and human primary cells derived from 
malignancies bearing protective over-expression of anti-apoptotic Bcl-2 family 
members (Lickliter et al, 2003; Oltersdorf et al, 2005, Campas et al, 2006; Konopleva 
et al 2006). Mushrooming reports suggest single agent efficacy and enhancement of 
conventional chemo- and immunotherapy-induced apoptosis upon combination with 
small-molecule Bcl-2 inhibitors in a wide variety of malignant cells and in vivo 
xenograft models (Chauhan et al, 2006; Shoemaker et al, 2006). New protocols 
employing such revolutionary compounds are currently studied with the therapeutic 
intent and have entered preclinical and phase 1 clinical evaluation (Graber, 2005). 
 It should be noted, however, that the underlying mechanisms of Bcl-2 antagonists 
are still intensively studied in view of the complex regulatory network of apoptotic 
pathways governed by the Bcl-2 family members. Alternative hypotheses have begun 
to emerge during recent years, including the role of the Bcl-2 family members in 
regulation of endoplasmic reticulum controlled apoptosis, autophagy and interaction 
with the up to date unidentified adapters able to activate initiator caspases other then 
caspase-9 (Milella et al, 2002; Thomenius and Distelhorst, 2003; Pattingre and 
Levine, 2006). Moreover recent report by van Delft et al (2006) has delivered 
intriguing questions regarding target specificity of the majority of putative “BH3 
mimetics”. Furthermore mechanisms of resistance to novel “BH3 mimetic” ABT-737 
have only been recently described by two independent groups (Konopleva et al, 2006; 
van Delft et al, 2006). 
 Taken together, the elucidation of delicate molecular balance between apoptosis 
and survival delivered basics for our understanding of the molecular 
pathomechanisms underlying cancer development and progression. Moreover, thanks 
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to the seminal work of Dr Stan Korsmeyer proteins from the Bcl-2 family may soon 
be exploited with the therapeutic intent in a wide range of still incurable malignancies. 
It is, thus, tempting to speculate that inhibitors of Bcl-2-like proteins are one of the 
most promising experimental anti-cancer therapeutics of the XXI century. Further 
studies are necessary to develop more potent and selective inhibitors of Bcl-2 and 
related proteins, and gain further insights into the “devil dance” played by the 
members of the Bcl-2 family (Skommer et al, 2006).  
2.6.3 Engaging secretory pathway to combat malignancy 
 Although the burden of data indicates that elimination of hematopoietic malignant 
cells depends heavily on classical apoptotic pathways, the evidence is mounting that 
alternative apoptotic and non-apoptotic mechanisms may effectively contribute to 
tumor suppression (Ferri and Kroemer, 2001; Linder and Shoshan, 2006). A growing 
number of reports recognize endoplasmic reticulum and Golgi apparatus as key 
players in the sensing and execution of various death signals (refer to chapter 2.5.2). 
As the interest in the role of ER and Golgi during induction/execution of apoptosis 
has been gaining momentum, they simultaneously attract growing appreciation in the 
development of novel anti-cancer therapies (Ferri and Kroemer, 2001; Jäättela, 2004). 
 In this context, two recent studies indicated that malignant B lymphocytes feature 
not only increased mitochondrial content but also more elaborate endoplasmic 
reticulum (ER) network when compared to their normal counterparts (Carew et al, 
2004; Carew et al, 2006). Therefore, it has been postulated that ER-Golgi system may 
be imperative for endurance of malignant B-clones, and such reliance may reveal 
unique anti-cancer targets (Fig. 9) (Carew et al, 2006).  
 Pertinent to the therapy of B-CLL, the successful targeting of the ER-Golgi 
pathway with Brefeldin A (BFA) in fludarabine refractory CLL cells has recently 
provided novel insights on how to eradicate cancerous B-cells independently of their 
p53 status and pathological overexpression of Bcl-2, Bcl-XL, Mcl-1 and XIAP 
proteins (Carew et al, 2006). Brefeldin A, a fungal 16-membered macrolide isolated 
from Penicillium brefeldianum, exerts ER and Golgi stress via inhibition of ADP-
ribosylation factor (ARF). Subsequent decline in coatamer proteins assembly leads to 
the disruption of ER-Golgi vesicular transport, Golgi collapse due to the imbalance in 
retrograde transport and induction of apoptotic cell demise (Donaldson et al, 1992; 
Carew et al, 2006; Cheung et al, 2006). 
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Fig. 9 Mechanisms underlying expected efficacy of the drugs targeting secretory 
pathway 
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linked glycosylation, reportedly sensitizes human prostate cancer cells to TNF-related 
apoptosis-inducing ligand (TRAIL) (Shiraishi et al, 2005). Furthermore, pertinent to 
the role of SERCA pump in ER mediated apoptosis, modified thapsigargin (PSA-
activated thapsigargin) has recently been postulated as an investigational drug for 
prostate cancer (Denmeade and Isaacs, 2005). Finally, as an unfolded protein response 
(UPR) forms an important cytoprotective mechanism, a proteasome inhibitor 
bortezomib augmented tunicamycin- and thapsigargin-triggered apoptosis in 
pancreatic cancer cells (Nawrocki et al, 2005).  
 Taken together it is tempting to speculate that agents that disrupt the secretory 
pathway may represent a completely novel avenue in anti-cancer drugs development. 
Further studies are necessary to elucidate precise signalling pathways launched from 
ER-Golgi compartment and to develop more potent and selective drugs that activate 
ER-Golgi mediated cell demise in malignant cells.  
2.7 Cytometry in studies of tumor cell demise 
 Undisputable advantage of FCM technology is pronounced by the fact of powerful 
multiparameter analysis capability and rapid analysis times that it offers (Herzenberg 
et al, 2002; Shapiro, 2003). Nowadays, bench-top cytometers and high-speed sorters 
are capable of analyzing up to 16 optical parameters from a single cell, with 
acquisition rates exceeding 25 000 events per second, and accuracy of individual cell 
measurement approaching 1%, opening completely new horizons for the cell biology 
research (Bernas et al, 2006).  Moreover as flow cytometry allows single cell analysis, 
the heterogeneity of population is preserved and enables quantitative discrimination of 
discrete cell subpopulations (Darzynkiewicz et al, 2001). Thus, FCM overcomes 
common problems of traditional techniques like fluorimetry, spectrofotometry, etc., 
involving considerable averaging of the results from a given sample. Novel 
technologies like cell imaging in flow and laser scanning cytometers deliver even 
more sophisticated features that combine superior statistical power of cytometric 
analysis coupled with high-resolution imaging capabilities (Darzynkiewicz et al, 
1999; Darzynkiewicz et al, 2001; Deptala et al, 2001; Smolewski et al, 2001; George 
et al, 2004). 
As apoptosis is a complex, finely controlled process of great relevance in tissue 
homeostasis and pathogenesis it is of no surprise that cytometry found its noteworthy 
applications in cell death studies. The majority of classical apoptosis features can be 
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rapidly examined by both flow and image cytometry, that have proven to be reliable 
and flexible platforms in a wide spectrum of research and clinical applications 
(Darzynkiewicz et al, 1997; Halicka et al, 1997; Bedner et al, 1999; Smolewski et al, 
2003; Huang et al, 2005). Analysis of cell demise modes using fluorescently labeled 
functional probes permits also cell sorting with subsequent supplementary 
biochemical and molecular studies. Importantly, multiparameter data obtained by 
flow and image cytometry permit ultimate correlation of different cellular events at a 
time on a cell-by-cell basis (Rasola et al, 2001; Pozarowski et al, 2003). Not 
surprisingly the development of novel functional probes for cell death studies and 
thorough understanding of the exact mechanisms underlying properties of existing 
ones are of utmost importance for the progress in cell necrobiology (Darzynkiewicz et 
al, 1997; Darzynkiewicz et al, 2001). This is particularly relevant in view of the 
growing appreciation of the multitude of cell demise modes, and the need for sensitive 
and high-throughput applicable assays capable to discriminate them. 
In this context, patented by Molecular Probes SYTO probes are slowly gaining 
attention as relatively inexpensive, convenient to use and sensitive markers of 
apoptotic cell death (Frey, 1995; Poot et al 1997; van der Pol et al, 2003). SYTO dyes 
reportedly provide the  means for tracking apoptosis in diverse cell lines, primary 
cells and have been proved amenable for the development of multiparameter flow 
cytometry assays (Frey, 1995; Poot et al, 1997; Schuurhuis et al, 2001). They exhibit 
very low inherent fluorescence, with strong enhancement upon binding to DNA/RNA. 
Moreover, the SYTO-stained eukaryotic cells exhibit both nuclear and diffuse-
cytoplasmic staining pattern, the latter reportedly abolished after formaldehyde 
fixation (Broxterman et al, 1997; van Zandvoort et al, 2002; Mundy and Freudenrich, 
2006). Of note, SYTO probes are not exclusive DNA stains, as they have been 
successfully applied to visualize translocation of RNA granules in neurons and 
discriminate nuclear/mitochondrial DNA from cytoplasmic RNA using two-photon 
lifetime imaging (Knowles et al, 1996; van Zandvoort et al, 2002). Importantly some 
authors postulate also the reliability of at least some SYTO dyes as effective 
substrates in quantitative P-glycoprotein function measurement (Broxterman et al, 
1997; Schuurhuis et al, 2001; van der Pol et al, 2003). 
Although mounting evidence show equal or higher sensitivity of SYTO probes as 
compared to Annexin V based assays, the precise mechanism underlying SYTO 
differential staining of apoptotic and viable cells still remains unclear (Schuurhuis et 
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al, 2001; Sparrow and Tippett, 2005). The most widely embraced idea is the self-
quenching of SYTO molecules that follows changes in interprobe proximity during 
apoptotic chromatic condensation. Also the decrease in SYTO binding sites as the 
chromatin condensation and/or RNA degradation advances in the process of apoptosis 
has been postulated by some authors during recent years (Frey, 1995; Poot et al, 1997; 
Zandvoort et al, 2002). Finally, based on the observation that most of the SYTO dyes 
contain one net positive charge at neutral pH and therefore may resemble 
mitochondrial membrane potential (MMP)-sensitive probes, it has been also 
suggested that alterations in binding of SYTO to mitochondrial DNA or decrease in 
its ∆ψm-driven mitochondrial uptake may contribute to the overall reduction of SYTO 
fluorescence in apoptotic cells (Broxterman et al, 1997; van Zandvoort et al, 2002; 
Sparrow and Tippett, 2005). These noteworthy but so far limited data clearly call for 
further investigation with aim to reveal mechanisms responsible for a reduction of 
SYTO fluorescence in apoptotic cells as compared to viable cells. 
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3. Objectives of the study 
The specific aims of the project were to: 
(i) Assess for the first time the monotherapeutic efficacy of novel small-
molecule Bcl-2 inhibitor HA14-1 and evaluate its potential combinatorial 
treatment with conventional anti-cancer chemotherapeutics: 
dexamethasone, doxorubicin and vincristine in recently established 
follicular lymphoma (FL) cell lines. (Article I) 
(ii) Track the multitude of apoptotic events, cell cycle specificity and temporal 
relationship between caspase activation, mitochondrial membrane 
depolarization and plasma membrane permeabilization in FL cells upon 
stimulation with Bcl-2 antagonist HA14-1. (Article II) 
(iii) Assess for the first time the monotherapeutic potential of ER-Golgi 
transport disrupting agent Brefeldin A and follow up on the multitude of 
cell demise events using multiparameter flow cytometry in FL cell lines 
(Article IV) 
(iv) For the first time assess the potential of simultaneous treatment using 
Brefeldin A and the small-molecule Bcl-2 inhibitor HA14-1 or CD95 
cross-linking monoclonal antibody (Article IV) 
(v) Provide novel insight into mechanisms underlying SYTO probes staining 
properties in different cell death contexts, applying state-of-the-art 
multiparametric flow cytometry, and multicolor fluorescent microscopy 
(Article III) 
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4. Materials and methods 
4.1 Cells and culture 
 The origin and characteristics of human follicular lymphoma (FL) cell lines 
HF1A3, HF4.9 and HF28RA were as previously described (Eray et al, 2003). Cells 
were cultured in 100 ml (75 cm2) cell culture flasks (Sarstedt Inc, Newton, NC, USA) 
in RPMI 1640 medium (Cambrex Bio Science, Verviers, Belgium) supplemented with 
5% heat-inactivated FCS (EuroClone, Pero, Italy), 2 mM L-glutamine (Fluka Chemie, 
Buch, Switzerland), 200 µg/µl streptomycin (Cambrex), 240 IU/ml penicilin 
(Cambrex), 10 mM HEPES buffer (Cambrex), 0.1 mM NAA (Cambrex), 1 mM Na-
pyruvate (Cambrex) and 20 µM 2-mercaptoethanol (Fluka Chemie). All cell cultures 
were maintained at 37°C in a 5% CO2 humidified atmosphere. During experiments 
cells were always in asynchronous and exponential phase of their growth.  
 Multi drug resistance efflux pump status of HF1A3, HF4.9 and HF28RA cells 
was evaluated by flow cytometry using cyclosporine A (Sigma-Aldrich Corp., St 
Louis, MO, USA), verapamil (Alexis Biochemicals, Lausen, Switzerland), probenecid 
(Alexis Biochemicals) together with SYTO 16 probe (Molecular Probes, Eugene, OR, 
USA) as previously described (Broxterman et al, 1997). P-gp-attributable activity was 
not detected in any of the cell lines. 
 
4.2 Induction of apoptosis and primary necrosis 
 To induce apoptosis, follicular lymphoma cell lines were seeded on the 24 or 
48-well flat bottom polystyrene cell culture plates (Corning Inc, NY, USA), treated 
with various concentrations of: a small molecule Bcl-2 inhibitor HA14-1 (Alexis 
Biochemicals; 0-25 µM), Brefeldin A (Sigma; 0-1000 ng/ml), CD95 cross-linking 
antibody (clone CH11; Upstate, NY, USA; 0-1000 ng/ml), dexamethasone (Dex; 
Sigma; 0-1000 nM), cycloheximide (CHX; Sigma; 0-10 µg/ml), doxorubicin (Dox; 
Sigma; 0-1000 nM) vincristine (Vin; Sigma; 0-100 nM) and harvested at different 
times as indicated in the respective articles. Small molecule Bcl-2 antagonist HA14-1 
was dissolved in DMSO and, owing to its instability, stored at -70˚C in 1mM aliquots. 
A fresh aliquot was used for each experiment immediately after thawing. Due to light 
sensitivity of HA14-1 compound experiments were performed avoiding direct light 
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illumination. Brefeldin A was dissolved in DNA grade ethanol and aliquots were 
stored at -20ºC. 
 Primary necrosis was induced in HF1A3 cells by hyperthermia (56˚C; 5min or 
46˚C up to 6h), treatment with 1% sodium azide (NaN3; Sigma) for up to 4h, or 3% 
H2O2 for up to 45min.  
 In order to inhibit caspase-dependent cell death cells were pretreated for 2 hours 
with a pan-caspase inhibitor z-VAD-fmk (Calbiochem, Cambridge, MA, USA; 10-
100 µM), a caspase 3/7 inhibitor z-DEVD-fmk (Calbiochem) and a caspase 9 
inhibitor z-LEHD-fmk (Calbiochem) as described in the respective articles. Cathepsin 
and calpain inhibitors (Pepstatin A, MDL28170, PD150606, CA-074-Me, zFA-fmk, 
and ALLN) were generously provided by Dr M. Courtney (A.I. Virtanen Institute, 
Kuopio, Finland). All inhibitors were dissolved in DMSO and their aliquots stored at -
20ºC. In some experiments reactive oxygen species (ROS) scavengers: N-
acetylcysteine (NAC, Sigma) and ascorbic acid (AA, Sigma) were applied. Both 
compounds have been dissolved in PBS and their aliquots stored at -20ºC.  
 No loss of activity of any of the compounds was detected over the duration of 
the study. All compounds were diluted in complete cell culture medium to working 
stocks immediately before use. The final concentration of ethanol/DMSO in culture 
media did not exceed 0.2% (v/v), and no alterations in growth variables were detected 
in vehicle controls. 
  
4.3 Cell proliferation assays 
 To assess short-term proliferation effects, cells were seeded on the 96-well flat 
bottom polystyrene culture plates at initial concentration 250.000 cells/ml and treated 
with 0 – 100 ng/ml BFA in complete medium for 20h. Subsequently 1 µCi/ ml 
[methyl-3H]-thymidine was added for additional 4h incubation at 37ºC. The 
incorporated radioactive thymidine was quantified by scintillation counting with 
Microbeta counter (Perkin Elmer, Wellesley, MA, USA).  
 To examine long-term effects of BFA treatments, cells were seeded at initial 
concentration 100.000 cells/ml and treated with 0-75 ng/ml BFA for up to 5 days. At 
the indicated intervals, 20 µl cell samples were removed and viable cell number was 
assessed by standard Trypan Blue (Life Technologies, Grand Island, NY, USA) 
exclusion assay as previously described (Skommer et al, 2006). 
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4.4 MTT cytotoxicity assay 
 The cytotoxic effects of HA14-1 against follicular lymphoma cell lines were 
determined using the MTT assay ((3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl 
tetrazolium bromide) (Chemicon International, Temecula, CA, USA). Cells were 
seeded on the 96-well flat bottom polystyrene culture plates at initial concentration 
5000 cells/well and treated with varying concentrations of HA14-1 (0-25 µM) for 20 
h at 37˚C. Subsequently, the MTT solution was added and after 4 h of incubation the 
optical density (OD) was measured using microplate reader (Multiskan Plus, 
Labsystems, Finland). Extraction buffer was used as a blank control. The following 
formula was used to calculate cell viability: cell viability (%) = (OD of the experiment 
samples/OD of the control)x100. Sigmoidal dose-response curves were fitted to the 
mean cell viability plotted against log HA14-1 dose and lethal concentration 50% 
(LC50) values were calculated from the resulting curves using Prism 4.0 software 
(GraphPad Software Inc., San Diego, CA, USA). 
 
4.5 Flow cytometry and FACS sorting 
4.5.1 Analysis 
 Flow cytometry analyses was performed on a FACScan (Becton Dickinson, San 
Jose, CA, USA) analyzer, equipped with 15 mW, 488 nm Argon-ion laser as a main 
excitation source and a standard setting of band-pass (BP) filters: FL1 (530/30 BP for 
collection of: SYTO green dyes, YO-PRO 1, FAM-VAD-FMK, FAM-DEVD-FMK, 
JC9 monomers and FITC-conjugated mAb fluorescence signals), FL2 (585/42 BP for 
collection of: propidium iodide, JC9 dimers, TMRM, NAO and DHE fluorescence 
signals), FL3 (650 LP for collection of: 7-AAD fluorescence signals). Acquisition of 
10000 or 15000 events per each sample in 1024 channels resolution scale was done 
using CellQuest ver.3.3 software (Becton Dickinson) running under MacOS 8.1 
operating system (Apple, Cupertino, CA, USA). 
 Analyses requiring double laser excitation setup were performed on an EPICS 
Elite ESP (Coulter Corp., Miami, FL, USA) cell sorter, equipped with 15 mW air-
cooled Argon-ion laser operating at 488 nm excitation line and air-cooled He-Ne laser 
operating at 633 nm excitation line. Standard setting of band-pass (BP) filters was 
applied:  
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 - 488 nm excitation line: FL1 (525 BP for collection of: SYTO16 fluorescence  
  signals), FL2 (610 BP for collection of: propidium iodide fluorescence  
  signals) 
 - 633 nm excitation line: FL4 (675 BP for collection of: Annexin V-APC  
  fluorescence signals) 
 Acquisition of 10,000 events per each sample in 254 channels resolution scale was 
done using EPICS (R) Elite ver4.02 software (Coulter) running under DOS 3.07 
operating system (Microsoft). 
4.5.2 Cell sorting 
 Sorting of respective subpopulations was performed on EPICS Elite ESP 
(Coulter Corp., Miami, FL, USA) cell sorter using 488 nm Argon ion laser excitation 
line. Following band-pass filter configuration was applied: FL1 525 BP (SYTO16), 
FL2 610 BP (PI). Sort parameters and data acquisition were controlled by EPICS (R) 
Elite ver4.02 software (Coulter). Sort gates were drawn on bivariate FSC/SYTO16 
dot-plots around three apparent subpopulations: SYTO16high (deemed viable cells), 
SYTO16dim (deemed early apoptotic cells), and SYTO16low (deemed late 
apoptotic/necrotic cells). Sorting was performed using 3x Sort-Sense Quartz Flow 
Cell (Coulter) with 100 µm diameter jetting orifice and crystal frequency set at 22 
kHz.  
 To avoid destruction of sorted apoptotic subpopulations system pressure operated 
at 10 PSI and sort rates did not exceeded 3000 cells per second. All sorts were done 
using Purity1Recovery2 sort mode (Coulter) which allowed achieving ≥ 95% cell 
purity for each subpopulation. For subsequent fractional DNA content analysis at least 
1 x 106 cells and for FSC/SSC analysis and sort purity check at least 5 x 105 cells 
were sorted into cooled RPMI 1640 medium containing 20% FBS. Each experiment 
consisted of at least three independent sorts. 
 
4.6 Cell viability assessment 
4.6.1 SYTO 16 / PI assay 
 The analysis was performed as previously described (Serafeim et al, 2003). 
Cells were exposed to selected agents at a dose and for the time indicated in the 
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respective articles. Control and treated cells were harvested, washed with PBS and 
resuspended in PBS containing 250nM SYTO 16 probe (Molecular Probes) and 5 µg 
PI.  Following staining (20 min at RT in darkness) 500 µl of PBS containing 2% FBS 
(EuroClone) was added and cells were immediately analyzed on FACScan flow 
cytometer (Becton Dickinson). SYTO 16high / PIneg events were considered as viable 
cells.  
4.6.2 YO-PRO 1 / PI assay 
 The analysis was performed as previously described (Idziorek et al, 1995). Cells 
were exposed to selected agents at a dose and for the time indicated in the respective 
articles. Control and treated cells were harvested, washed with PBS and resuspended 
in PBS containing 250nM YO-PRO 1 probe (Molecular Probes) and 5 µg PI.  
Following staining (20 min at RT in darkness) 500 µl of PBS containing 2% FBS 
(EuroClone) was added and cells were immediately analyzed on FACScan flow 
cytometer (Becton Dickinson). Double negative events (YO-PRO 1neg / PIneg) were 
considered as viable cells.  
 
4.7 Evaluation of apoptotic features using flow cytometry 
4.7.1 SYTO 16 / PI assay 
 The staining was performed as described in 4.6.1. Analysis was as previously 
described (Serafeim et al, 2003). Briefly, SYTO 16high / PIneg events were considered 
as viable cells, SYTO 16dim / PIneg events were considered as apoptotic cells and 
SYTO 16neg / PI+ events were considered as late apoptotic/necrotic cells. 
4.7.2 Comparative assessment of SYTO green probes 
 All probes from SYTO green I family (SYTO11-16) were procured from 
Molecular Probes. SYTO reagents were initially diluted in DMSO (Sigma) to achieve 
stock concentrations of 1 mM. Aliquots of probes were then stored at -20°C in the 
dark. After the treatment with apoptosis- or primary necrosis- inducing agents, cells 
were collected, rinsed with PBS to remove phenol red containing RPMI medium, and 
re-suspended in the 100 µl PBS containing selected SYTO dyes and plasma 
membrane permeability marker, propidium iodide (PI, Sigma, 5 µg/ml). Final 
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concentrations of SYTO dyes were as follows: 100 nM (SYTO11 and SYTO13), 200 
nM (SYTO12), 250 nM (SYTO16), and 500 nM (SYTO14 and SYTO15). After 20 
min incubation at RT in the darkness, 500 µl of PBS containing 2% FBS (EuroClone) 
was added and cells were immediately subjected to the flow cytometric analysis.  
 Assay conditions for SYTO green probes were determined after dose and time-
course optimization studies. No sizeable differences in the efficiency of SYTO 
staining were detected when dye-loading was performed in PBS, PBS supplemented 
with 2% FBS, HEPES or complete RPMI 1640 medium or at 0.25 - 4 x 106 
cells/staining mixture cell density. Additionally, even 5-10 min loading at 37°C was 
as efficient as longer incubation times (up to 60 min tested) at 37°C, and as 20 min 
loading at RT. 
4.7.3 YO-PRO 1 / PI assay 
 The staining was performed as described in 4.6.2. Analysis was as previously 
described (Idziorek et al, 1995). Briefly, viable cells exclude both dyes (YO-PRO 1neg 
/ PIneg events), early apoptotic cells characterized by initial cell membrane 
permeabilization are stained only with small cation YO-PRO 1 while excluding still 
propidium iodide (YO-PRO 1+ / PIneg events). Cells in late stages of apoptosis and 
primary necrotic cells are characterized by pronounced loss in cell membrane 
integrity, and are thus permeable to both YO-PRO 1 and PI probes (YO-PRO 1+ / PI+ 
events). 
4.7.4 Phosphatidylserine exposure assay 
 In some experiments (data not exploited in any of the articles) Annexin V assay 
(APC – conjugated; Alexis Biochemicals) was used as a confirmatory technique, 
assessing externalization of phosphatidylserine (PS) on the outer leaflet of the plasma 
membrane. Staining and analysis was performed according to manufacturer 
instructions. Briefly after incubation with selected drugs cells were washed with 
Annexin V Binding Buffer (AVBB; 10 mM HEPES/NaOH pH 7.4 supplemented with 
140 mM NaCl and 2.5 mM CaCl2). Next cells were resuspended in 100 µl AVBB 
containing permeability marker propidium iodide (PI; Sigma; 5µg/ml) and 1.5 µl of 
Annexin V reagent was added. After 20 minutes incubation (RT in darkness) 500 µl 
of AVBB was added and cells were immediately subjected to the flow cytometric 
analysis. Viable cells were considered as Annexin Vneg / PIneg events (containing PS 
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on the inner leaflet of the plasma membrane and excluding propidium iodide), early 
apoptotic cells were considered as Annexin V+ / PIneg events (with externalized PS 
while still excluding propidium iodide), whereas cells in late stages of apoptosis and 
primary necrotic cells were considered as Annexin V+ / PI+ events (with pronounced 
loss in cell membrane integrity). 
4.7.5 Fractional DNA content analysis 
 Cells were exposed to HA14-1 or Brefeldin A at a dose and for the time 
indicated in the respective articles. Cells were then harvested, washed twice with PBS 
and fixed overnight with ice-cold 70% ethanol. Subsequently cells were centrifuged 
and incubated with RNase A (Sigma; 300 µg/ml) and propidium iodide (PI; Sigma; 16 
µg/ml) for 1h at 37ºC. The cell cycle profile was determined on a FACScan flow 
cytometer (Becton Dickinson). 
4.7.6 Caspase activation 
 Caspase activation was assessed supravitally by cell permeable FLICA 
(Fluorescently Labeled Inhibitors of Caspases) reagent as previously described 
(Smolewski et al, 2001; Pozarowski et al, 2003; Skommer et al, 2006). 
Cells were exposed to HA14-1 or Brefeldin A at a dose and for the time indicated in 
the respective articles, harvested, washed and resuspended in 100µl of fresh medium, 
followed by staining with FLICA reagent (FAM-VAD-FMK – pan-caspase activation 
or FAM-DEVD-FMK – caspase 3 activation; Alexis Biochemicals) according to the 
manufacturer's instructions (1h at 37°C under 5% CO2 in darkness). Next, cells were 
washed twice with ice-cold PBS and counterstained with plasma membrane 
permeability marker propidium iodide (PI; Sigma; 5µg/ml) for 5 minutes at RT in 
darkness. Finally 500 µl of PBS containing 2% FBS (EuroClone) was added and cells 
were immediately subjected to the flow cytometric analysis. 
4.7.7 Mitochondrial membrane depolarization 
 Loss of mitochondrial membrane potential was assessed by flow cytometry 
using TMRM and JC9 probes (Molecular Probes) as previously described (Pritchard et 
al, 2001; Castedo et al, 2002). Cells were exposed to HA14-1 or Brefeldin A at a dose 
and depolarization for the time indicated in the respective articles, harvested, washed 
and resuspended in 100µl PBS containing 150 nM TMRM or 1 µg JC9 probe. After 
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15 min (TMRM) or 20 min (JC9) incubation at 37°C, 500 µl of PBS containing 2% 
FBS (EuroClone) was added and cells were immediately subjected to the flow 
cytometric analysis. 
4.7.8 YO-PRO 1 / TMRM assay 
 Combined assay allowing simultaneous detection of mitochondrial membrane 
depolarization and varying stages of plasma membrane integrity was applied based on 
TMRM and YO-PRO 1 dyes (Molecular Probes).  
Cells were stimulated with Brefeldin A at a dose and for the time indicated, harvested, 
and resuspended in 100µl of PBS containing 150 nM TMRM (Molecular Probes) to 
assess the depolarization of mitochondrial membrane. After 15 min loading at 37°C, 
cells were counter-stained with YO-PRO 1 (250 nM; Molecular Probes) for 20 
minutes at RT to simultaneously detect early and late stages of plasma membrane 
permeability. Following staining 500 µl of PBS containing 2% FBS (EuroClone) was 
added and cells were immediately subjected to the flow cytometric analysis. 
4.7.9 Detection of reactive oxygen species (ROS) 
Dihydroethidine (DHE) staining 
 Intracellular generation of reactive oxygen species (ROS) was directly 
determined using DHE probe (Molecular Probes) as previously described (Castedo et 
al, 2002). Cells were stimulated with HA14-1 at a dose and for the time indicated, 
harvested, and resuspended in 100µl of PBS containing 2.5 µM DHE. Following 
staining (20 min at 37°C) 500 µl of PBS containing 2% FBS (EuroClone) was added 
and cells were immediately subjected to the flow cytometric analysis. 
 
Nonyl-acridine orange (NAO) staining 
 Intracellular generation of reactive oxygen species (ROS) leading to 
peroxidation of mitochondrial cardiolipin was determined using NAO probe 
(Molecular Probes) as previously described (Castedo et al, 2002). Cells were 
stimulated with HA14-1 at a dose and for the time indicated, harvested, and 
resuspended in 100µl of PBS containing 100 nM NAO. After 20 min incubation at 
37°C, 500 µl of PBS containing 2% FBS (EuroClone) was added and cells were 
immediately subjected to the flow cytometric analysis. 
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4.8 Multiparameter flow cytometry assays 
4.8.1 SYTO16 / TMRM / 7-AAD assay 
 After induction of apoptosis, cells were collected, washed twice with PBS to 
remove phenol-red containing RPMI media, and stained in 100 µl PBS containing 
SYTO16 (250nM) and TMRM (150nM) for 15 min at 37ºC in darkness. Next, 
samples were briefly cooled on ice to the RT, and plasma membrane permeability 
marker, 7-AAD (Molecular Probes), was added to a final concentration of 5 µg/ml. 
Samples were subsequently incubated for 5 min at RT in darkness. Finally 500 µl of 
PBS containing 2% FBS (EuroClone) was added and cells were immediately analyzed 
on the flow cytometer. 
4.8.2 FLICA / TMRM / 7-AAD assay 
 Multiparametric assay that allows simultaneous tracking of caspase activation 
(by FLICA), mitochondrial membrane depolarization (by TMRM) and plasma 
membrane permeability (by 7-AAD) was applied as previously described (Smolewski 
et al, 2001; Pozarowski et al, 2003). Cells were exposed to HA14-1 or Brefeldin A at 
a dose and for the time indicated in the respective articles, harvested, washed and 
resuspended in 100µl of fresh medium, followed by staining with FLICA (FAM-
VAD-FMK; Alexis Biochemicals) according to the manufacturer's instructions (1h at 
37°C). Next, cells were washed twice with ice-cold PBS, resuspended in PBS 
containing 150 nM TMRM (Molecular Probes) and incubated for 15 min at 37°C. 
Cells were subsequently counter-stained with 7-AAD probe (Molecular Probes; 5 
µg/ml) for 3-5 minutes at RT. Finally 500 µl of PBS containing 2% FBS (EuroClone) 
was added and cells were immediately subjected to the flow cytometric analysis.  
4.8.3 Cell cycle specificity of caspase activation 
 Analysis was as previously described (Smolewski et al, 2001; Pozarowski et al, 
2003). Cells were exposed to HA14-1 or Brefeldin A at a dose and for the time 
indicated in the respective articles. FLICA reagent (FAM-VAD-FMK; Alexis 
Biochemicals) was added for the last hour of HA14-1 or Brefeldin A treatment. 
Following FLICA staining cells were washed twice with PBS and fixed for 15 min in 
ice-cold 1% v/v methanol-free formaldehyde. Samples were subsequently 
permeabilized in 70% ethanol at -20°C for at least 2 h. Following permeabilization 
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cells were centrifuged and stained with propidium iodide (PI; Sigma; 10 µg/ml) in the 
presence of RNase A (100 µg/ml) for 1 h at 37°C. Green fluorescence of FAM-VAD-
FMK was analyzed using logarithmic scale, and red fluorescence of PI using linear 
scale on FACScan flow cytometer. 
 
4.9 Intracellular staining for Bcl-2 
 Follicular lymphoma cells were fixed and permeabilized using Fix&Perm kit 
(Caltag Laboratories, Burlingame, CA, USA) according to the manufacturer's 
instructions and incubated in the presence of 10µl FITC-conjugated anti-Bcl-2 
antibodies (Caltag Laboratories) or the FITC-conjugated IgG1 isotype-control 
antibody (BD Biosciences, San Diego, CA, USA). Following 20 min incubation 500 
µl of PBS containing 2% FBS (EuroClone) was added and cells were immediately 
analyzed on FACScan analyzer (Becton Dickinson) with 15000 events acquired per 
sample. Bcl-2 expression was calculated as the difference in the mean fluorescence 
intensity (MFI) between the anti-Bcl-2 sample and the isotype control. 
 
4.10 Evaluation of apoptotic features using fluorescent 
microscopy 
4.10.1 Hoechst 33342 
 Control and HA14-1- or Brefeldin A-treated cells were rinsed with culture 
media and stained with Hoechst 33342 dye (Alexis Biochemicals; 1.5 µg/ml) for 20 
min at RT. Following staining, cells were wet-mounted and imaged by an Olympus 
IX70 microscope (equipped with a cooled Apogee KX85 CCD camera) or Olympus 
AX70 Provis microscope (equipped with a cooled FVII digital camera; Olympus Co. 
Ltd., Tokyo, Japan). 100W Hg burners were used as an epifluorescent light sources. 
40x and 60x air objective lenses and appropriate fluorescence mirror units (Ex/Em for 
Hoechst 33342 355/465 nm) were applied to collect cell images. Cell images were 
captured by MicroSuiteTM FIVE imaging software (Olympus) running under 
Windows XP Professional (Microsoft Corp., Redmond, WA, USA).  
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4.10.2 SYTO 16 / TMRM / Hoechst 3342 
 HF1A3/HF4.9 control cells, or cells treated with 1 µM Dex, were rinsed with 
culture media and stained for 15 min with 150 nM TMRM (Molecular Probes) and 
2500 nM SYTO16 (Molecular Probes) in RPMI medium at 37ºC. Subsequently cells 
were transferred to the RT and counter-stained with Hoechst 33342 (Alexis 
Biochemicals; 1.5 µg/ml) for additional 20 min. Following staining, cells were wet-
mounted and imaged by an Olympus AX70 Provis microscope equipped with FVII 
digital camera (Olympus Co. Ltd., Tokyo, Japan). Air objective lenses (60x) and 
appropriate fluorescence mirror units (Ex/Em for: SYTO16 490/520 nm, TMRM 
530/615 nm, Hoechst 33342 355/465 nm) were applied for obtaining respective 
images. Cell images were captured by MicroSuiteTM FIVE imaging software 
(Olympus) running under Windows XP Professional (Microsoft). 
 
4.11 Confocal microscopy 
 For SYTO/TMRM co-localization studies, 1x106 HF1A3 cells were stained with 
250 nM SYTO16 and 150 nM TMRM (Molecular Probes) in PBS for 15 min at 37ºC. 
Following staining, cells were imaged using Nikon Eclipse inverted microscope 
equipped with UltraVIEW confocal scanning system (Perkin Elmer, USA). Cell 
images were captured and analyzed by Perkin Elmer Imaging Suite version 5.5 
software running under Windows 2000 (Microsoft Corp.). 
 
4.12 Transmission electron microscopy (TEM) 
 HF1A3 cells (1x106 cells/ml) were cultured with or without BFA for 24h, 
harvested and fixed. Sample processing for electron microscopy was carried our by 
the BioMater Centre at the University of Kuopio according to standard protocols. 
Briefly, the post-fixed sections were dehydrated in a series of ethanol and embedded 
in Epon resin (Ladd Research Industries, USA). The polymerized resin blocks were 
sectioned with a Reichert Ultracut-E ultramicrotome (Reichert-Jung, Austria). 50 nm 
sections were subsequently collected onto copper grids and stained with uranyl 
acetate. Specimens were examined under a JEOL JEM1200EX transmission electron 
microscope (JEOL, Tokyo, Japan) using 80 kV accelerating voltage and 14 sec 
exposure time. Digital micrographs were collected using BioScan 792 digital camera 
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(GATAN, Munich, Germany) controlled by Digital Micrograph 3.1 software 
(GATAN, Coronado Lane, Pleasanton, CA). 
 
4.13 Western blotting 
 Control and BFA-treated cells were resuspended in the lysis buffer (Cell 
Signaling Technologies, Beverly, MA, USA), and proteins isolated according to 
manufacturer’s instructions. Equal amounts of protein were separated by SDS-PAGE 
and transferred to nitrocellulose membrane (Amersham Pharmacia Biotech; 
Buckinghamshire, UK). Membranes were incubated at +4ºC overnight with anti-
PARP (SantaCruz Biotechnology Inc, Santa Cruz, CA, USA), anti-caspase 2 
(SantaCruz Biotechnology), anti-BIP (Abcam), and anti-actin (Sigma) primary 
antibodies. The ER residual chaperone BIP/GRP78 was chosen as a marker of ER 
stress-induction by Brefeldin A, prior to electron microscopy analysis of BFA-treated 
follicular lymphoma cells. 
Corresponding peroxidase-conjugated secondary antibodies were from Zymed (San 
Francisco, CA, USA). Immunodetection was performed with ECL Western blotting 
kit (Amersham Pharmacia Biotech). 
 
4.14 Data analysis 
4.14.1 Flow cytometry data analysis 
 Flow cytometry data was analyzed and presented using WinMDI ver. 2.8 
software developed by Dr J. Trotter (BD Pharmingen, San Diego, CA; freely 
available at http://facs.scripps.edu/software.html), offline Summit v3.1 software 
(Dako Cytomation, Fort Collins, CO, USA) both running under Windows XP 
Professional operating system (Microsoft) and CellQuest ver.3.3 software (BD 
Biosciences, San Jose, CA, USA) running under MacOS 8.1 operating system (Apple, 
Cupertino, CA, USA). 
4.14.2 Image analysis 
 Image analysis and presentation was carried out using ImageJ open source 
platform (developed at the National Institutes of Health, Bethesda, USA; freely 
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available at http://rsb.info.nih.gov/ij/) running under Windows XP Professional 
(Microsoft) and Perkin Elmer Imaging Suite version 5.5 software (Perkin Elmer) 
running under Windows 2000 (Microsoft Corp.). 
4.14.3 Drug dose response analysis 
 Sigmoidal dose-response curves were fitted to the mean cell viability plotted 
against log HA14-1 or Brefeldin A dose and lethal concentration 50% (LC50) values 
were calculated from the resulting curves using Prism 4.0 software (GraphPad 
Software Inc.). 
4.14.4 Combination index calculations 
 Fractional survival was calculated as a fraction of cells killed by the individual 
drug or the combination in drug-treated versus untreated cells, and data were fitted to 
the Hill equation (Prism 4.0, GraphPad Software Inc.). Logarithmic transformation of 
the Hill equation (as done in the median-effect plot analysis by Chou and Talalay) 
wasn’t performed due to reported reduced accuracy and precision of the regression-
derived IC50 and curve shape parameters (Zhao et al, 2004). The combination index 
(CI) values were calculated based on the following equation:  
CI= (D)1(Dx)1 + (D)2/(Dx)2 + (D)1(D)2/(Dx)1(Dx)2 
where (D)1 and (D)2 are the doses of drug 1 and drug 2 that have x effect when used 
in combination, and (Dx)1 and (Dx)2 are the doses of drug 1 and drug 2 that have the 
same x effect when used alone. The CI values indicate synergism (<1), additivity (=1) 
or antagonism (>1). The CIs of 0.1-0.3, 0.3-0.7 and 0.7-0.85 are considered to 
indicate strong synergism, synergism and moderate synergism, respectively. 
4.14.5 Statistical analysis 
 Results shown on dot plots and photographs are representatives of at least three 
independent experiments and SD values between experiments did not exceed ± 7%. 
Student's t-test was applied for comparison between groups using SPSS (Chicago, IL, 
USA) version 11.0 for Windows. Significance was set at p<0.05. Pearson correlation 
analysis was performed using Excel 2000 software (Microsoft). 
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5. Results and discussion 
5.1 Small molecule Bcl-2 inhibitor HA14-1 induces apoptosis and 
potentiates activity of selected anti-cancer drugs in follicular 
lymphoma cells (articles I & II) 
 In many tumors the physiological capacity to remove damaged/superfluous cells is 
subdued, either because a pathological overexpression of prosurvival family members 
is present or because p53 dependent pathway is inactivated. Nevertheless a gross 
majority of tumors maintain components of death machinery. Thus, an attractive 
therapeutic approach is to overcome the intrinsic resistance to apoptosis and activate 
existing cell demise pathways (Spurgers et al, 2006). Due to the reported importance 
of the anti-apoptotic Bcl-2 family members in a multistep carcinogenesis, they have 
recently attracted considerable attention as forthcoming targets for selective anti-
cancer regimens (Letai, 2005). Especially the family of small organic molecules 
(BH3-mimetics) able to bind to the hydrophobic groove of Bcl-2/Bcl-XL and displace 
Bax/Bak and BH3-only proteins, may represent a future avenue for a selective anti-
Bcl-2 strategy (Cory and Adams, 2005; Letai, 2005; Letai, 2006). 
In this context, we have for the first time demonstrated monotherapeutic potential 
of a small molecule Bcl-2 antagonist, HA14-1, against follicular lymphoma cells with 
t(14;18) translocation and resulting Bcl-2 overexpression. HA14-1, a recently 
discovered cell permeant and nonpeptidic compound able to trigger dissipation of the 
mitochondrial membrane potential and cytochrome c release, was one of the first Bcl-
2/Bcl-XL antagonists developed by virtual library screening (Wang et al, 2000). 
Moreover, low concentrations of HA14-1 were reported to exert minimal toxicity 
towards normal human hematopoietic cells, presenting a potential therapeutic window 
(Lickliter et al, 2003). 
5.1.1 Monotherapeutic potential of HA14-1 against follicular lymphoma 
cells 
 In agreement with previous studies on a number of hematopoietic malignancies, 
we showed for the first time that follicular lymphoma cells are sensitive to HA14-1-
induced cell killing. HA14-1 cytotoxicity was mediated through apoptosis, as depicted 
by nuclear fragmentation, morphological changes, reduced SYTO 16 fluorescence 
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and reduction of DNA content to sub-G1 levels. In all FL cells examined, HA14-1 
induced a prominent decline in cell viability, however, the HF4.9 cell line was the 
most sensitive to HA14-1-mediated cytotoxicity (LC50 of 4.5µM compared to LC50 of 
12.6 µM for HF1A3 and LC50 of 8.1 µM for HF28RA cell lines), featuring at the same 
time the highest expression of Bcl-2 protein.  
Consistent with previous reports, we showed that cytotoxicity mediated by a small 
molecule Bcl-2 inhibitor HA14-1 in FL cells proceeded through rapid (4h) dissipation 
of the ∆Ψm, elaborate generation of reactive oxygen species (ROS) and caspase 
activation. Although contradictory reports about HA14-1-induced caspase activation 
do exist in the literature, the HA14-1 mediated cell killing of FL cells was fully 
inhibited by means of pharmacological caspase inhibitors (Wang et al, 2000; Chen et 
al, 2002; An, et al, 2004). Both Z-VAD-fmk (inhibitor of broad range caspases), Z-
LEHD-fmk (inhibitor of caspase 9), and Z-DEVD-fmk (inhibitor of caspase 3) 
completely abrogated the oligonucleosomal DNA fragmentation. Of importance, pan-
caspase inhibitor z-VAD-fmk abolished both morphological changes and loss of cell 
membrane integrity evaluated by FSC/SSC changes and PI uptake by flow cytometry. 
Our results are in line with recent reports by Chauhan et al (2006) and van Delft et al 
(2006) reporting complete caspase dependence of the novel small molecule BH3 
mimetic ABT-737 in multiple myeloma cells and murine embryonic fibroblasts, 
respectively. Interestingly, novel findings identify also that HA14-1 can induce both 
apoptosis and autophagy in L1210 murine leukemia cells and in the absence of 
caspase activation HA14-1-mediated cell death is shifted towards autophagic program 
(Kessel and Reiners, 2006). 
5.1.2 Mechanisms of HA14-1-induced apoptosis 
 The temporal and quantitative relationship between mitochondrial membrane 
depolarization and caspase activation still remains ambiguous. Moreover it is still 
debatable whether caspase activation is restricted only to cells with mitochondrial 
membrane depolarization, or can occur autonomously. In this context, it has recently 
been proposed that the HA14-1-evoked loss of ∆ψm is insufficient for the initiation of 
full apoptotic response in the absence of caspase cascade activation (Milella et al, 
2002). Following this lead, we investigated the quantitative relationship between ∆Ψm 
loss and caspase activation in HA14-1 challenged FL cells. We employed both 
pharmacological inhibitor studies and novel state-of-the-art multiparametric flow 
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cytometry assay combining simultaneous tracking of mitochondrial membrane 
depolarization (by TMRM probe), caspase activation (by FLICA probe) and cell 
membrane permeability (by 7-AAD probe), analogical to one used by Pozarowski et 
al (2003). Tracking kinetic events in HF4.9 cells revealed that following HA14-1 
treatment caspase activation occurs solely as a consequence of mitochondrial breach. 
In line with others (Milella et al, 2002), the kinetic study revealed also that at longer 
exposition times (over 24h) mitochondrial breach slightly lessened (indicative of 
transient nature of ∆ψm loss), whereas the number of cells with activated caspases 
constantly increased over time. As a result, at 48h time point the majority (approx. 
92%) of cells with ∆ψm loss featured caspase activation. Importantly, a very careful 
monitoring of early changes (0-4h in 15 min intervals) following HA14-1 treatment 
did not allow detection of population with caspase activation and preserved ∆ψm. In 
agreement with our previous results pre-treatment with a pan-caspase inhibitor 
zVAD-fmk prevented caspase activation although did not obstruct the HA14-1-
elicited ∆ψm loss. Additionally, hindering mitochondrial permeability transition pore 
(PTP) with cyclophilin D inhibitor (cyclosporin A, CsA) partially protected HF4.9 
cells against HA14-1 induced ∆ψm collapse and caspase activation. Thus, we provided 
new evidence that mitochondrial apoptosis induced by a small molecule Bcl-2 
inhibitor may be at least partially dependent on PTP. 
 In the context of molecular mechanisms underlying Bcl-2 antagonists’ action, a 
recent report by van Delft and colleagues (2006) argues that many BH3 mimetics, 
including HA14-1, BH3I-1, Compound 6, Antimycin A, Chelerythrine and Gossypol, 
do not reflects BH3-only proteins mediated cell killing. Data provided by authors 
indicate that above mentioned putative BH3 mimetics potently induce cell killing in 
Bax/Bak DKO MEFs in both short term and long term colony formation assays. It is a 
very intriguing finding, since Bax -/- and Bax -/- Bak -/- MEFs have been previously 
reported resistant to HA14-1 cell killing (Chen et al 2002; An et al, 2004). Moreover, 
Bax translocation to mitochondria was reported compulsory for HA14-1-elicited cell 
demise (Chen et al 2002; An et al, 2004). Undoubtedly further studies are required to 
understand molecular basis of apoptosis induction by BH3 mimetics and to develop 
novel, more specific protein-protein disruptors.  
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5.1.3 Cell cycle specificity of HA14-1-evoked apoptosis 
 The knowledge on a cell cycle specificity of apoptosis induction is of clinical 
importance by offering hints how to design effective multidrug treatment regimens. 
Moreover, since cell cycle preferential killing may depend on cell type, combining 
drugs that target distinctive phases of the cell cycle is likely to be therapeutically 
beneficial. While the definite phase of the cell cycle at which HA14-1-treated cells are 
apoptosing has not been addressed, we employed a flow cytometric assay based on 
bivariate analysis of the DNA content and FLICA binding implemented by 
Pozarowski and colleagues (2003). In this assay cell cycle position is measured for 
both apoptotic and non-apoptotic cells, allowing direct verification of caspase 
activation in relation to the cell-cycle. It should be noted that while FLICA specificity 
towards individual caspases, in terms of exclusivity of their binding to individual 
caspases, may be questioned (Pozarowski et al 2003), application of these reagents 
allows for convenient dectection of caspases activation, identification of apoptotic 
cells and location of their position in the cell cycle. We revealed that following a low 
dose HA14-1 challenge follicular lymphoma cells undergo apoptosis mainly from G1 
phase, and to a lesser extent from S- and G2/M phases. Because cell cycle specificity 
may substantially differ in the case of early and delayed apoptosis, we determined the 
effect of transient exposure of FL cells to a high HA14-1 concentration, followed by 
cell growth in drug-free medium. Here again the vast majority of cells underwent 
apoptosis mainly from G1 and S phases of the cell cycle. Based on our results it is 
tempting to speculate that combining the small molecule Bcl-2 inhibitor HA14-1 with 
drugs arresting cells in G1 and/or S phase, or drugs inducing apoptosis in G2/M phase 
may be therapeutically beneficial. Only recently, our conclusions have been 
substantiated by two excellent reports from Michael Andreeff’s group at MD 
Anderson Cancer Center in Houston (Kojima al, 2006; Konopleva et al, 2006). 
Similarly to us, authors illustrate that initiation of mitochondrial apoptosis in response 
to novel BH3 mimetic ABT-737 is constrained predominantly to cells in the G1 cell 
cycle phase. Based on their previous report (Konopleva et al, 2006) Kojima and 
colleagues deliver also convincing evidence that relative resistance of G2/M cells to 
the BH3 mimetic can be correlated with their higher Bcl-2 expression and Bcl-2 
phosphorylation at Ser70. This is of particular interest as the regulation of Bcl-2 family 
proteins during cell cycle remains still elusive. Illustration that the increase of Bcl-2 
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levels occurs with the progression from G1 to G2 phase may clarify increased 
sensitivity of G1 cells to both spontaneous, ABT-737- and HA14-1-induced 
apoptosis. Furthermore in line with our earlier conclusions, Kojima and colleagues 
demonstrated that small molecule Mdm2 antagonist Nutlin-3a, arresting cells in G1 
and inducing apoptosis predominantly in S and G2/M phase, potently synergizes with 
ABT-737 in acute myeloid leukemia cells. Taken together, there is a substantial 
excitement that combination of novel protein-protein inhibitors will form cornerstones 
of novel regimens of substantial therapeutic prospective. 
5.1.4 Efficacy of combinatorial treatment between the Bcl-2 antagonist 
HA14-1 and conventional anti-cancer chemotherapeutics 
 Finally, we were first to prove the applicability of a combinatorial treatment with 
the small molecule Bcl-2 antagonist HA14-1 and selected conventional 
chemotherapeutics in follicular lymphoma cells. At simultaneous exposition scenarios 
HA14-1 significantly increased the cytotoxicity of dexamethasone (Dex), whereas no 
significant enhancement of vincristine (Vin) and doxorubicin (Dox) action was 
observed in follicular lymphoma cells. In each cell line tested the concentrations of 
HA14-1, were only mildly cytotoxic when administered alone (below 15% of killing). 
Thus, the augmentation in lethality upon Dex/HA14-1 co-administration was beyond 
the effects of either of these agents alone, indicative of synergistic action. Of 
importance, the addition of HA14-1 induced a 2.5-6 fold increase in the early 
apoptotic population compared to cells exposed to Dex alone when examined by 
SYTO16/PI assay. 
 To evaluate the prospects of sequential drug administration, we subsequently 
challenged follicular lymphoma cells with HA14-1 for 24 hours, the medium was 
removed and the second cytotoxic agent (Dex, Dox or Vin) was added for another 24 
hours. Cell viability was evaluated by SYTO 16/PI assay at the end of the incubation 
period. The results indicate that HA14-1 pretreatment sensitized FL cells to Dex and 
Dox and the cytotoxicity of the combinations was beyond the action of any of these 
agents alone. Moreover the combined effects between Vin and HA14-1 were lower 
than additive. The CI values, obtained from fixed molar ratio experiments, confirmed 
the synergy between HA14-1 and Dex (the CIs < 1 for simultaneous and sequential 
administration) and Dox (the CIs < 1 for sequential administration). Correspondingly 
to our results, the schedule dependent enhancement of paclitaxel cytotoxicity by a 
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novel small molecule inhibitor of Bcl-XL A385358 has recently been reported by 
Shoemaker et al (2006) in small cell lung carcinoma cells. 
 Overall, we showed for the first time the capacity of the small-molecule Bcl-2 
antagonist HA14-1 to enhance Dex and Dox-induced cytotoxicity and apoptosis in 
follicular lymphoma cell lines. Concentrations of the HA14-1 used in our experiments 
were substantially below the previously reported in vitro toxic level for normal 
hematopoietic cells and these findings suggest prospective clinical effectiveness of 
BH3 mimetics. Results of our study indicated for the first time not only the single 
agent efficacy of BH3 mimetic in follicular lymphoma cells but also suggested that 
combinatorial treatment with BH3 mimetics may be an efficient strategy to render 
cytotoxic agents more efficient at lower systemic doses. In this context, oblimersen 
sodium (G3139) and (-)gossypol (a natural small molecule inhibitor of Bcl-2/Bcl-XL) 
have been shown to enhance response to VAD (vincristine, adriamycin and 
dexamethasone) regimen in multiple myeloma patients, and to CHOP 
(cyclophosphamide-doxorubicin-vincristine-prednison) regimen in diffuse large cell 
lymphoma cells, respectively (van de Donk et al, 2004; Mohammad et al, 2005). Of 
particular interest, ours and others findings have been recently substantiated by a 
report demonstrating synergistic action between Dex and a novel synthetic BH3 
mimetic ABT-737 in multiple myeloma cells (Chauhan et al, 2006). Furthermore, 
very recent reports by Oltersdorf et al (2005), Konopleva et al (2006) and van Delft et 
al (2006) delivered unprecedented data to support the notion of combinatorial 
treatment with the small molecule Bcl-2 antagonist ABT-737 and selected 
conventional chemotherapeutics (doxorubicine, cisplatine, paclitaxel, Ara-C, 
etoposide) in a variety of tumor models.  
   
5.2 ER-Golgi network as a novel anti-cancer target in follicular 
lymphoma (article IV) 
A growing number of reports recognize endoplasmic reticulum (ER) and Golgi 
apparatus as key players in the sensing and execution of cell demise signals. As the 
interest in the role of ER and Golgi during induction/execution of apoptosis has been 
gaining momentum, they also attract growing attention in the development of novel 
targets for selective anti-cancer therapies (Ferri and Kroemer, 2001; Linder and 
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Shoshan, 2005; Carew et al, 2006). In this context, it has been recently demonstrated 
that malignant B-CLL blasts feature enlarged mitochondrial and ER compartments as 
compared to their normal counterparts (Carew et al, 2006). Postulated theory links 
elaborate ER-Golgi system to the endurance of malignant clones and suggests unique 
anti-cancer target with reasonable therapeutic window (Carew et al, 2006).  
 
Hence, we have for the first time demonstrated monotherapeutic potential of ER-
Golgi transport disrupting agent, Brefeldin A (BFA), against follicular lymphoma 
cells bearing t(14;18) translocation. In agreement with previous studies on a number 
of hematopoietic malignancies and solid tumors, we provided for the first time 
evidence on nanomolar efficacy of Brefeldin A against follicular lymphoma cells. In 
the long-term (5-day) growth experiments we revealed that the administration of low 
doses of BFA (25 ng/ml) completely inhibits growth of HF4.9 and HF28RA cells. 
Somewhat higher BFA doses (75 ng/ml) were required to achieve the same effect in 
HF1A3 cells. Moreover, short-term studies (24h) provided strong evidence that cell 
proliferation was inhibited in a dose-dependent manner and, depending on the cell 
line, almost complete cessation of 3H-thymdine incorporation was observed at 50-75 
ng/ml of BFA. By implementing YO-PRO1/PI viability assay, we also revealed that 
both diminished cell proliferation and enhanced cell death appeared to associate in the 
long-term growth cessation triggered by BFA. 
 Brefeldin A-mediated cell killing proceeded through apoptosis, as represented by 
a plethora of markers including: chromatin condensation and nuclear fragmentation, 
cell shrinkage, reduced SYTO 16 fluorescence, selective uptake of cationic probe 
YO-PRO1, Annexin V binding and reduction of DNA content to sub-G1 levels. 
Moreover, the distinctive apoptotic morphology was accompanied by caspase 
activation, as determined by immunoblot analysis of PARP (poly-ADP-ribose 
polymerase) cleavage and by FLICA (herein FAM-VAD-FMK) staining.  
 Interestingly, contradictory reports about BFA-induced caspase activation exist in 
the literature. Herein pre-treatment with a pan-caspase inhibitor zVAD-fmk at 50µM, 
rescued BFA-treated FL cells only partially. It is of special interest as previous results 
employing FLICA assay depicted clearly that the entire apoptosing population in 
BFA-treated cells featured caspase activation. We have always obtained similar 
results whichever FLICA reagents were employed (FAM-VAD-FMK or FAM-
DEVD-FMK). Because apoptotic cascade can be initiated from Golgi apparatus 
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through caspase 2 which is approximately 55 times less sensitive to inhibition by 
zVAD-fmk (compared to caspase 3/7), we examined caspase 2 processing by Western 
blotting in BFA stimulated FL cells (Garcia-Calvo et al, 1998; Hicks and Machamer, 
2005). Indeed, noticeable reduction in levels of procaspase-2 was detected upon BFA 
stimulation in all cell lines tested which is in line with several previous reports 
showing the involvement of caspase 2 in BFA-mediated cell demise (Carew et al, 
2006; Cheung et al, 2006). Moreover, any significant protection against BFA-
triggered cell death was conferred by neither cathepsin nor calpain inhibitors 
(MDL28170, PD150606, CA-074-Me, zFA-fmk, and ALLN) applied in the present 
study. Protein synthesis inhibitor cycloheximide (CHX) was able to significantly 
restore viability of HF1A3 and HF4.9 cells (Fig. 10), whereas ROS scavengers, 
ascorbic acid and N-acetyl cysteine, exerted no protective effects (Fig. 11). Although 
appealing, data from CHX studies should be interpreted with considerable caution. It 
is very plausible that reduced protein load to the ER and, thus, reduced ER stress may 
reflect enhanced viability in BFA stimulated cells. 
 
Fig. 10 Protein synthesis inhibitor cycloheximide (CHX) confers partial protection 
against BFA-induced cell death.  
FL cells were pre-incubated for 1 hour with 100 ng/ml CHX. Subsequently, BFA was 
added to a final concentration of 100 ng/ml and cells were incubated for the 24 hours. 
As a control FL cells were stimulated with 100 ng/ml CHX or 100 ng/ml BFA alone. 
Cell viability was determined by SYTO16/PI and YO-PRO 1/PI staining, as described 
under Materials and Methods. The results represent mean ± SD of at least three 
independent experiments. 
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Fig. 11 Analysis of ROS dependence in Brefeldin A (BFA)-induced cell death. 
A) HF1A3 cells were pre-incubated for 2 hour with 5 mM N-acetylcysteine (NAC). 
Subsequently, BFA was added to a final concentration of 100 ng/ml and cells were 
incubated for the 24 hours. As a control FL cells were stimulated with 5 mM NAC or 
100 ng/ml BFA alone. Cell viability was determined by SYTO16/PI and YO-PRO 1/PI 
staining, as described under Materials and Methods. The results represent mean ± SD 
of at least three independent experiments. B) HF1A3 cells were pre-incubated for 2 
hour with 250 µM ascorbic acid (AA). Subsequently, BFA was added to a final 
concentration of 100 ng/ml and cells were incubated for the 24 hours. As a control FL 
cells were stimulated with 250 µM AA or 100 ng/ml BFA alone. Cell viability was 
determined by SYTO16/PI and YO-PRO 1/PI staining, as described under Materials 
and Methods. The results represent mean ± SD of at least three independent 
experiments. 
A)       B) 
 
 Quantitative relationship between ∆Ψm loss and caspase activation in BFA 
challenged FL cells revealed that mitochondrial breach proceeded slowly during the 
24 hours of BFA treatment, and was accompanied by increased FLICA binding, 
indicative of caspase activation. Similarly to HA14-1 studies (refer to chapter 5.1) we 
were unable to detect cell population with activated caspases and preserved 
mitochondrial membrane potential, suggesting that mitochondrion stands at the nexus 
of apoptotic program also in this model. Almost all cells with ∆ψm collapse appeared 
to have activated caspases and upon BFA removal these cells did not recover but 
instead progressively acquired late apoptotic/necrotic phenotype (characterized by cell 
membrane permeability to 7-AAD). Our data support the hypothesis that MMP is a 
rate-limiting step during BFA-induced cell killing and are in line with earlier report 
showing that two distinct MMP inhibitors (Bcl-XL and vMIA) can significantly 
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protect against BFA-, tunicamycin- and thapsigargin-induced apoptosis (Boya et al, 
2002). 
 
 While the cell cycle dependence of apoptosis initiation by ER and/or Golgi 
stressors has not been investigated, we employed a flow cytometric assay based on 
bivariate analysis of the DNA content and FLICA binding (refer to chapter 5.2 and 
Pozarowski et al, 2003) to track caspase activation in relation to the cell-cycle 
position. Cell cycle specificity studies revealed that BFA induced caspase activation 
from all cell cycle phases, but with clear predominance of cells at G1 phase. To the 
best of our knowledge this was the first study to address this issue with respect to 
BFA-induced cell death. 
 
 Since a large number of reports have demonstrated that elevated Bcl-2/Bcl-
XL/Mcl-1 expression is associated with a poor clinical response, a combinatorial 
strategies aimed at diverse apoptotic elements may offer substantial therapeutic 
promise. Brefeldin A has been previously suggested as an investigational anticancer 
agent targeting secretory pathway, however its potential interactions with other 
apoptosis-inducing compounds remain surprisingly unexplored (Sausville et al, 1996; 
Shao et al 1996; Chapman et al, 1999; Carew et al, 2006). Merely one study by Shao 
and colleagues (1996) reported synergistic induction of apoptosis upon combinatorial 
treatment of human promyelocytic leukemia cells with BFA and staurosporine. 
Hence, we investigated the potential therapeutic utility of combined treatment 
between BFA vs. a small molecule Bcl-2 inhibitor (HA14-1) and BFA vs. a model 
trigger of death-receptor pathway (CD95 cross-linking mAb). As discussed in the 
chapter 5.2, we have previously demonstrated the potential of BH3 mimetic HA14-1 
to induce apoptosis in a single-agent and combinatorial treatment scenarios. 
Strikingly, upon co-treatment of FL cells with HA14-1 and BFA we observed an 
enhanced cell killing, whereas the co-stimulation anti-CD95 mAb increased the 
efficacy of Brefeldin A to a much lesser degree. Together, these data clearly point out 
that combinatorial targeting of diverse cell death pathways may improve anticancer 
action of ER/Golgi stressors. It would be extremely interesting to test this premise 
further in primary patient-derived cells and in vivo models.  
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 In closing, the secretory pathway attracts slowly mounting interests as a 
prospective anti-cancer target. Our results support the premise that malignant B-
lineage cells, engaged in intense secretory function, are highly vulnerable to the 
interruption of ER-Golgi homeostasis. Recent studies by Tinhoffer et al (2002) and 
Anether et al (2003) have delivered novel insights into elimination of fludarabine 
refractory B-CLL primary cells and T-acute lymphoblastic leukemia cells by 
Tetrocarcin A, an another naturally occurring antibiotic that initiates apoptosis 
through ER-stress. Of particular interest, N-linked glycosylation inhibitor, 
tunicamycin, was recently reported to sensitize human prostate cancer cells to TNF-
related apoptosis-inducing ligand (TRAIL) (Shiraishi et al, 2005). Taken together it is 
tempting to contemplate that ER stressors may represent a completely novel avenue in 
the development of future anti-cancer drugs.  
 
5.3 Towards an understanding of apoptosis detection by cell 
permeable SYTO probes (article III) 
 
  Cell permeable SYTO dyes are gaining escalating interest as sensitive, reliable 
and easy to use markers of apoptotic cell demise (Frey, 1995; Poot et al 1997; van der 
Pol et al, 2003; Sparrow and Tippett, 2005). Noticeably, the observable fact of 
differential SYTO staining of apoptotic cells compared to normal cells is still not fully 
elucidated. Moreover as a rising number of researchers apply SYTO dyes for 
assessment of apoptosis by flow cytometry and fluorescence microscopy, there is 
definitively a need for deciphering the phenomena underlying staining characteristics 
of those unique probes (Schuurhuis et al, 2001; van Zandvoort et al, 2002; Sparrow 
and Tippett, 2005).  
Recent reports have shown comparable or higher sensitivity of SYTO probes as 
compared to Annexin V based assays (Schuurhuis et al, 2001; Sparrow and Tippett, 
2005). Herein, we have reconfirmed those results by applying for the first time a 
triplicate staining with Annexin V-APC/SYTO 11/PI probes (Fig 12). 
 In the present survey we also showed that SYTO dyes from the green family 
(SYTO11-16) have overlapping staining characteristics, supplementing the findings 
reported by Poot and colleagues (Poot et al, 1998).  
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Fig. 12 Similarities between SYTO 11 and Annexin V staining patterns upon induction 
of apoptosis. HF4.9 cells were exposed to 1 µM Dex for 24 hours, followed by the 
triplicate staining with SYTO11, Annexin V (APC conjugated) and propidium iodide 
(PI) probes. The bivariate distribution of SYTO 11 vs. PI was derived from the 3D 
plot. Histograms and FSC/SSC plots were derived from respective gates (R1, R2, R3) 
drawn on SYTO 11/PI bivariate plot. Green events (R1) - live cells, Blue events (R2) – 
apoptotic cells, Red events (R3) – late apoptotic/necrotic cells (PI-positive). Note that 
cells with loss of SYTO 11 fluorescence to dim values predominantly stain with 
Annexin V. Three independent experiments yielded comparable results. Similar 
results were obtained in two other cell lines, HF1A3 and HF28RA (not depicted). 
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apoptotic/necrotic (SYTOlow/PI+) subpopulations, whereas SYTO12 and 15 could 
evidently distinguish the same subpopulations only on FSC/SYTO bivariate plots.  
The discrimination of viable, apoptotic and late apoptotic/necrotic cells by SYTO 
probes was confirmed after back-gating every subpopulation onto FSC/SSC and 
FSC/PI bivariate plots. Interestingly, the number of SYTOdim cells after staining with 
any of SYTO11, 13, 14 and 16 dyes correlated well (r2 ≥ 0.98; Pearson and Lee linear 
correlation test). The lack of the decrease in SYTO15 fluorescence to dim values in 
response to apoptotic trigger was in general accordance with study by Poot and 
colleagues (Poot et al, 1998). To the best of our knowledge, however, this was the 
first report showing the clear discrimination of viable, apoptotic and late 
apoptotic/necrotic populations based on the bivariate FSC vs. SYTO12/15 dot plots. 
 In the present report, applying both the state-of-the-art multiparametric flow 
cytometry and multicolor cell imaging, we identified also for the first time different 
SYTO staining characteristics upon apoptotic and oncotic stimuli. It has been showed 
previously that SYTO probes are specific markers of caspase dependent apoptotic cell 
demise (Fig. 13) and loss of SYTO16 fluorescence can be considered as a truly 
apoptotic feature (Poot et al, 1997; van der Pol et al, 2003; Sparrow and Tippett, 
2005). Interestingly there are currently no reports describing behavior of SYTO dyes 
under oncotic/necrotic conditions or during autophagic or caspase independent cell 
death modes. Herein, we showed that rapid loss of the SYTO16 fluorescence to low 
values is noticeable after challenging FL cells with diverse oncotic stimuli. We 
observed that exposition of cells to relatively harsh oncotic stimuli (1% NaN3 – 4 
hours, 56°C – 5 min) resulted in manifestation of predominant SYTOlow/PI+ 
phenotype, representative of cells with a compromised plasma membrane. Apparent 
enlargement in the number of SYTOhigh/PI- cells was also observable after stimulating 
FL cells with sodium azide or exposing them to +46ºC. 
 
Fig. 13 Analysis of caspase dependence in SYTO16 staining profiles after induction of 
apoptosis in FL cells. 
HF1A3 cells were pre-incubated for 1 hour with 20 µM pan-caspase inhibitor 
(zVADfmk) or 20 µM caspase 8 inhibitor (zIETDfmk). Subsequently, agonistic anti-
Fas mAb (clone CH11) was added to a final concentration of 10 ng/ml and cells were 
incubated for the 24 hours, followed by staining with SYTO16 and PI probes as 
described in Materials and Methods section. As a control FL cells were treated with 
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10 ng/ml anti-Fas mAb or 20 µM zVADfmk/ zIETDfmk alone. Cell debris showing 
extremely low FSC/SSC values were excluded electronically from each plot. Results 
are representative of four independent experiments.  
 
 
 Finally, prompt by recent reports, we also tracked similarities and divergences 
between SYTO16 and TMRM (tertramethylrhodamine methyl ester; ∆Ψm, sensitive 
probe) (Poot et al, 1997; Sparrow and Tippett, 2005). Although simultaneous loss of 
both dyes has been previously observed by some authors and this has even led to the 
proposal of SYTO staining dependence on ∆Ψm we hypothesized that differences 
between staining properties of SYTO16 and TMRM can be unveiled upon shorter 
treatment settings (Broxterman et al, 1997; Sparrow and Tippett, 2005). When 
stimulated with conventional inducers of apoptosis (Dex, CHX, agonistic anti-Fas 
mAb) the loss of SYTO16 and TMRM fluorescence occurred concomitantly (Fig. 14). 
Interestingly, even during short-term kinetic experiments with those agents, we 
continuously noticed only parallel loss in fluorescence of both probes. No 
intermediate events (SYTOdim/TMRMhigh and/or SYTOhigh/TMRMlow) were observed 
between apoptotic and normal cells. 
 To validate our findings from multiparameter flow cytometry, we have also 
performed fluorescence microscopy after tri-color staining with SYTO16 / TMRM / 
Hoechst 33342 probes, as described in Materials and Methods. Upon treatment with 
Dexamethasone or agonistic anti-Fas monoclonal antibody, dying cells displayed loss 
of tertramethylrhodamine methyl ester staining (considered as a marker of ∆ψm loss) 
and reduction of SYTO fluorescence (reflecting “dim” subpopulation previously 
distinguished by flow cytometry). All SYTOdim/TMRM- cells exhibited enhancement 
of Hoechst 33342 fluorescence with apparent apoptotic features: fragmentation of 
nucleus and cell shrinkage. 
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Fig. 14 Resemblance between SYTO16 vs. TMRM staining profiles after induction of 
apoptosis in FL cells. 
HF1A3 cells were left untreated (control) or stimulated with Dexamethasone (Dex; 1 
µM, 24h), followed by triplicate staining with SYTO16, TMR and /7-AAD probes as 
described in Materials and Methods section. 3D plots and bivariate SYTO16 vs 
TMRM plots (after electronic exclusion of debris and 7-AAD+ events) indicate 
concomitant and progressive loss of SYTO and TMRM fluorescence. x, y and z axis on 
the 3D plots represent 7-AAD, TMRM and SYTO16 fluorescence respectively. Note 
the excellent correlation between number of SYTO16low/7-AAD- and TMRMlow/7-AAD- 
events. Cell debris showing extremely low FSC/SSC values were excluded 
electronically from each plot. Results are representative of four independent 
experiments. Similar results were obtained with HF4.9 and HF28RA cell lines (not 
depicted). 
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stains independently of TMRM. Guided by the results, we therefore assumed that at 
least under some circumstances it should be possible to monitor different staining 
profiles between SYTO16 and ∆Ψm, sensitive probe TMRM.  
 In this context we demonstrated for the first time that stimulation of FL cells with 
mitochondrial uncoupler FCCP and a small-molecule Bcl-2 inhibitor, HA14-1, induce 
distinct staining profiles with the decrease in TMRM fluorescence preceding the loss 
of SYTO16 fluorescence. The initial loss of TMRM fluorescence upon HA14-1 
treatment appeared to precede the loss of SYTO16 fluorescence, the latter trailing to 
dim values over longer exposure time. Importantly, FCCP and HA14-1-mediated 
reduction of SYTO16 fluorescence was blocked by pharmacological inhibition of 
caspases (with a pan-caspase inhibitor, z-VAD-fmk). Our data reveal, thus, that loss 
of SYTO16 appears to be a caspase-dependent event and loss of SYTO fluorescence 
to dim values is not a mere indicator of ∆ψm dissipation, postulated by some authors 
(Broxterman et al, 1997; Sparrow and Tippett, 2005). Moreover, we provided strong 
evidence that commonly observed similarities between SYTO and TMRM may stem 
from the fast kinetics of apoptotic events once cell death program is already initiated.  
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6. Concluding remarks 
A. Small molecule Bcl-2 inhibitor HA14-1 induces apoptosis and synergizes with 
selected anti-cancer drugs in follicular lymphoma cells (articles I & II) 
 We have for the first time shown that follicular lymphoma cells are sensitive 
to HA14-1-induced cytotoxicity mediated through the intrinsic apoptotic pathway. 
The cell killing induced by a small molecule Bcl-2 inhibitor HA14-1 proceeded 
through rapid dissipation of the ∆Ψm, generation of reactive oxygen species and 
caspase-dependent apoptosis. Based on results obtained from pharmacological 
inhibitor studies and novel state-of-the-art multiparametric flow cytometry assays 
we conclude that: 1) Upon binding of HA14-1 into the BH-3 binding pocket of 
Bcl-2 (and possibly other Bcl-2 related proteins) caspase activation occurs only as 
a consequence of mitochondrial disruption; 2) HA14-1-evoked apoptosis appears 
to be at least partially PT-dependent, providing additional evidence to a widely 
discussed controversy over generality of PT as a primary mechanism for 
mitochondrial outer membrane permeabilization and apoptosis. 
 Moreover, we also pioneered in addressing the cell cycle specificity of HA14-
1 action using multivariate flow cytometry approaches. As the vast majority of 
cells underwent apoptosis mainly from G1 and S phases of the cell cycle, it is 
tempting to speculate that combining the small molecule Bcl-2 inhibitor HA14-1 
with drugs arresting cells in G1 and/or S phase, or drugs inducing apoptosis in 
G2/M phase may be therapeutically beneficial. 
 Finally, we showed for the first time the ability of the small-molecule Bcl-2 
antagonist HA14-1 to enhance susceptibility towards dexamethasone and 
doxorubicin-induced cytotoxicity (in schedule dependent and independent 
manner, respectively) and apoptosis in follicular lymphoma cell lines.  
Based on our results and mushrooming reports it is tempting to speculate that 
synthetic inhibitors of antiapoptotic Bcl-2-like proteins are among the most 
promising experimental anti-cancer therapeutics of the XXI century. Further 
studies are unquestionably necessary to develop more potent and selective 
inhibitors of Bcl-2 and related proteins, and gain further insights into the “devil 
dance” played by the members of the Bcl-2 family. 
 85
B. Engaging secretory pathway by Brefeldin A as a novel mean to combat 
follicular lymphoma (article IV) 
 We have for the first time shown that follicular lymphoma cells are sensitive 
to Brefeldin A-induced cytotoxicity associated with the mitochondrial breach and 
activation of caspase 2. We noted also the lack of autophagic morphology, upon 
BFA stimulation, reportedly associated with ER stress in some other models. 
In conceptual agreement with other reports, we supported here the nanomolar 
efficacy of Brefeldin A against follicular lymphoma cells with survival driving 
Bcl-2 overexpression. Our results support the premise that malignant B-lineage 
cells, engaged in intense secretory function, are highly vulnerable to the 
interruption of ER-Golgi homeostasis even if protected by pathological 
overexpression of anti-apoptotic proteins.  
 To the best of our knowledge we were also first to address the cell cycle 
specificity of BFA in malignant B cells. Utilizing a multiparameter flow 
cytometry approach we demonstrated that the immense majority of cells 
underwent apoptosis from G1 phase of the cell cycle.  
 Finally, pertinent to the treatment of B-cell malignancies we report here for 
the first time the effects of an ER-Golgi stressor, Brefeldin A (BFA), alone and in 
combination with a small molecule Bcl-2 inhibitor HA14-1 in the human FL cell 
lines bearing t(14;18) translocation. Of importance for future anti-cancer 
regimens, small molecule Bcl-2 antagonist, HA14-1 significantly enhanced BFA- 
mediated cytotoxicity and apoptosis, revealing previously unexplored means to 
augment ER-stress mediated cell killing. 
 
C. Mechanisms underlying SYTO staining properties in different cell death 
contexts (article III)  
 In the survey, we have for the first time presented diverse SYTO 16 staining 
characteristics upon apoptotic and oncotic stimuli. Moreover by comparing SYTO 
16 with a ∆Ψm, sensitive probe TMRM we were first to report a drastically distinct 
behavior of those dyes under very short exposure of follicular lymphoma cell to a 
mitochondrial uncoupler FCCP and a small-molecule Bcl-2 inhibitor, HA14-1. 
Several important conclusions can be drawn based on our findings:  
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¾ a sole loss of ∆ψm apparently does not lead to a decrease in SYTO16 
fluorescence, which results instead from caspase-dependent changes occurring 
downstream of mitochondrion during apoptosis 
¾ commonly detected resemblance between SYTO16 and TMRM staining 
profiles may stem from the fact that many apoptotic stimuli induce 
mitochondrial rupture and engage downstream apoptotic targets within 
relatively short time  
¾ amplification of protease cascade in the later stages of apoptotic cell demise 
leads to an even more pronounced loss of SYTO fluorescence (represented by 
SYTOlow values) 
¾ it can not be excluded that caspase-dependent alterations in mitochondria 
structure and/or function may contribute to the loss of SYTO fluorescence 
during apoptosis. 
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